WO2011040509A1 - 2,3-ジヒドロ-1h-インデン-2-イルウレア誘導体及びその医薬用途 - Google Patents
2,3-ジヒドロ-1h-インデン-2-イルウレア誘導体及びその医薬用途 Download PDFInfo
- Publication number
- WO2011040509A1 WO2011040509A1 PCT/JP2010/067047 JP2010067047W WO2011040509A1 WO 2011040509 A1 WO2011040509 A1 WO 2011040509A1 JP 2010067047 W JP2010067047 W JP 2010067047W WO 2011040509 A1 WO2011040509 A1 WO 2011040509A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- mmol
- dihydro
- methoxy
- inden
- Prior art date
Links
- NKMGXWGXMVRSQX-FBBABVLZSA-N CC(C)(C)c(cc1NC(N[C@@H](Cc(cc2)c3cc2OC)[C@@H]3O)=O)cc([C@H](C(F)(F)F)O)c1OC Chemical compound CC(C)(C)c(cc1NC(N[C@@H](Cc(cc2)c3cc2OC)[C@@H]3O)=O)cc([C@H](C(F)(F)F)O)c1OC NKMGXWGXMVRSQX-FBBABVLZSA-N 0.000 description 1
- NKMGXWGXMVRSQX-SLYNCCJLSA-N CC(C)(C)c(cc1[C@H](C(F)(F)F)O)cc(NC(N[C@H](Cc(cc2)c3cc2OC)[C@H]3O)=O)c1OC Chemical compound CC(C)(C)c(cc1[C@H](C(F)(F)F)O)cc(NC(N[C@H](Cc(cc2)c3cc2OC)[C@H]3O)=O)c1OC NKMGXWGXMVRSQX-SLYNCCJLSA-N 0.000 description 1
- 0 CC(C)(C)c1c(*)c(*)c(*)c(NC(NC2C(*)c3c(C=C)c(*)c(*)c(*)c3C2*)=O)c1 Chemical compound CC(C)(C)c1c(*)c(*)c(*)c(NC(NC2C(*)c3c(C=C)c(*)c(*)c(*)c3C2*)=O)c1 0.000 description 1
- GFOWXDHPFXLSSK-KAGYGMCKSA-N CC1(CCOCC1)c(cc1NC(N[C@H](Cc2ccccc22)[C@H]2O)=O)cc([C@H](C(F)(F)F)O)c1OC Chemical compound CC1(CCOCC1)c(cc1NC(N[C@H](Cc2ccccc22)[C@H]2O)=O)cc([C@H](C(F)(F)F)O)c1OC GFOWXDHPFXLSSK-KAGYGMCKSA-N 0.000 description 1
- GFOWXDHPFXLSSK-CBQOVEMMSA-N CC1(CCOCC1)c(cc1[C@@H](C(F)(F)F)O)cc(NC(N[C@H](Cc2ccccc22)[C@H]2O)=O)c1OC Chemical compound CC1(CCOCC1)c(cc1[C@@H](C(F)(F)F)O)cc(NC(N[C@H](Cc2ccccc22)[C@H]2O)=O)c1OC GFOWXDHPFXLSSK-CBQOVEMMSA-N 0.000 description 1
- NKFFZUYPLPKMBZ-UHFFFAOYSA-N COc(c(C(C(F)(F)F)O)cc(N1CCOCC1)c1)c1NC(NC(Cc1ccccc11)C1O)=O Chemical compound COc(c(C(C(F)(F)F)O)cc(N1CCOCC1)c1)c1NC(NC(Cc1ccccc11)C1O)=O NKFFZUYPLPKMBZ-UHFFFAOYSA-N 0.000 description 1
- LMHHFZAXSANGGM-UHFFFAOYSA-N NC(C1)Cc2c1cccc2 Chemical compound NC(C1)Cc2c1cccc2 LMHHFZAXSANGGM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Definitions
- the present invention relates to a 2,3-dihydro-1H-inden-2-ylurea derivative and its pharmaceutical use.
- Inflammatory cytokines are biological factors that play an important role in the suppression of pathogenic infections, etc., but when inflammatory cytokines are produced excessively, toxic shock syndrome, osteoarthritis, diabetes or inflammation May cause inflammatory diseases such as genital bowel disease.
- TNF ⁇ tumor necrosis factor ⁇
- infliximab which is a TNF ⁇ monoclonal antibody, acts as a functional antagonist of TNF ⁇ in vivo and has been developed as a therapeutic agent for inflammatory diseases such as Crohn's disease and uveitis due to Behcet's disease (non- Patent Documents 1 and 2).
- p38MAPK is a homologue of mitogen-activated protein kinase (hereinafter referred to as MAPK), and is activated by stimulation with ultraviolet irradiation, lipopolysaccharide (hereinafter LPS), inflammatory cytokines, and the like. It is known to promote the production of inflammatory cytokines such as TNF ⁇ .
- Patent Documents 1 to 11 disclose low molecular weight compounds having p38 MAPK inhibitory activity
- Patent Documents 12 to 14 disclose compounds having a 2,3-dihydro-1H-inden-2-ylurea structure.
- Patent Documents 12 to 14 disclose compounds having a 2,3-dihydro-1H-inden-2-ylurea structure.
- Allergic dermatitis is a disease predisposed to an allergic reaction and is characterized by chronic itching and rashes on the face, neck, elbows and knees.
- the number of patients with allergic dermatitis is increasing year by year due to an increase in allergens and changes in dietary habits, and the symptoms are becoming more serious.
- pharmacotherapy is mainly used, and corticosteroids, immunosuppressants, antihistamines and the like are used as therapeutic agents.
- Inflammatory bowel disease is a general term for diseases such as ulcerative colitis and Crohn's disease that cause inflammation and ulcers mainly in the mucous membrane of the large intestine, and is an intractable chronic disease of unknown cause. Since it has many early onset, diarrhea, bloody stool, etc. continue for a long time, and relapses and remissions are repeated, the influence on patients' QOL (Quality of life) is large, but the number of patients is increasing rapidly in recent years.
- component nutrition therapy and drug therapy are mainly performed.
- As therapeutic agents for drug therapy 5-aminosalicylic acid preparations, steroids, immunosuppressants, antibody preparations and the like are used.
- Pain is classified into two types: acute pain, which is physiological pain, and chronic pain represented by inflammatory pain and neuropathic pain.
- Chronic pain is one in which pain persists for a long time after the substantial tissue damage that caused the initial pain has disappeared, and is considered to be caused by abnormalities in the transmission, control, or cognitive mechanism of pain.
- Chronic pain is often resistant to opioid analgesics and the like, is refractory and pain persists for a long time, and sensory abnormalities such as hyperalgesia and allodynia occur, thus significantly reducing the patient's QOL.
- pharmacotherapy is mainly used.
- non-steroidal anti-inflammatory drugs NSAIDs
- neuropathic pain is used for non-steroidal anti-inflammatory drugs.
- Anticonvulsants and antidepressants are used.
- biologics such as infliximab can be expected to have a significant therapeutic effect as a functional antagonist.
- administration as an injection is essential, there is a burden on the patient.
- the administered biologic is recognized as a foreign substance in the body, there is a risk that the medicinal effect is greatly reduced.
- generation of TNF (alpha) is anxious, the low molecular weight compound which does not have a side effect, such as hepatotoxicity, has not been found yet.
- component nutrition therapy In the treatment of inflammatory bowel disease, component nutrition therapy has few side effects, but it has a large impact on the patient's QOL in the long term, and there are cases of poor response in pharmacotherapy, such as infections and complications There are many problems.
- Non-steroidal anti-inflammatory drugs such as diclofenac sodium are effective in the treatment of inflammatory pain, but side effects such as gastrointestinal disorders are observed.
- side effects such as gastrointestinal disorders are observed.
- gabapentin an anticonvulsant Is effective, but there are still side effects such as quite strong sleepiness and lightheadedness.
- the present invention has an object to provide a low molecular weight compound having a p38 MAPK inhibitory activity and a TNF ⁇ production inhibitory activity associated therewith, realizing a good pharmacokinetic profile and a reduction in hepatotoxicity as a pharmaceutical, and a pharmaceutical use thereof. To do.
- Another object of the present invention is to provide a therapeutic or prophylactic agent for allergic dermatitis, inflammatory bowel disease and pain containing this low molecular weight compound as an active ingredient.
- a novel 2,3-dihydro-1H-inden-2-ylurea derivative or a pharmacologically acceptable salt thereof has significant p38 MAPK inhibitory activity and It has TNF ⁇ production-suppressing activity associated therewith, has an excellent pharmacokinetic profile and low toxicity, and has an excellent medicinal effect against allergic dermatitis, inflammatory bowel disease and pain As a result, the present invention has been completed.
- the present invention provides a 2,3-dihydro-1H-inden-2-ylurea derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof and a medicament containing these as active ingredients.
- k represents an integer of 1 to 4
- m represents an integer of 2 to 5
- n represents an integer of 0 to 4
- R 1 and R 2 each independently represent hydrogen Or an alkyl having 1 to 6 carbon atoms
- each R 3 is independently substituted with an alkyl having 1 to 6 carbon atoms (one or more halogens, R 6 O— and / or (R 6 ) 2 N— R 6 O—, (R 6 ) 2 N— or halogen
- R 4 and R 5 each independently represents an alkyl having 1 to 6 carbon atoms (one or more halogens, R 6 O— and / or (R 6 ) 2 N— may be substituted)
- C 3-8 cycloalkyl (optionally substituted with 1 to 3 independent R 6 s
- the present invention provides a 2,3-dihydro-1H-inden-2-ylurea derivative represented by the general formula (Ia) or a pharmacologically acceptable salt thereof and a medicament containing these as active ingredients.
- n represents an integer of 0 to 4
- R 3a represents R 6 O— or (R 6 ) 2 N—
- R 3b represents hydrogen
- R 4a represents alkyl having 1 to 6 carbon atoms (which may be substituted with one or more halogen atoms, R 6 O— and / or (R 6 ) 2 N—), R 6 O— , (R 6 ) 2 N— or halogen
- R 4b is substituted with alkyl having 1 to 6 carbon atoms (one or more halogens, R 6 O— and / or (R 6 ) 2 N—
- a cycloalkyl having 3 to 8 carbon atoms (which may be substituted with 1 to 3 independent R 6 s
- the bonded carbon atom may be replaced by a nitrogen atom
- R 6 O—, (R 6 ) 2 N—, R 6 C (O) NH—, R 6 S (O) 2 NH—, R 6 C (O) —, R 6 OC (O) —, (R 6 ) 2 NC (O) —, cyano or halogen represents R 6
- X represents R 6 O— or (R 6 ) 2 N—. . ]
- the present invention also relates to allergic dermatitis, inflammatory bowel disease and pain comprising the above 2,3-dihydro-1H-inden-2-ylurea derivative or a pharmacologically acceptable salt thereof as an active ingredient.
- a therapeutic or prophylactic agent is provided.
- the 2,3-dihydro-1H-inden-2-ylurea derivative of the present invention and a pharmacologically acceptable salt thereof have a p38 MAPK inhibitory activity and an accompanying TNF ⁇ production inhibitory activity, and have a good pharmacokinetic profile Therefore, it is useful as a therapeutic agent for inflammatory diseases based on p38MAPK activation and TNF ⁇ production.
- the present invention can also be used as a therapeutic or prophylactic agent for allergic dermatitis, inflammatory bowel disease and pain with reduced side effects.
- the 2,3-dihydro-1H-inden-2-ylurea derivative of the present invention (hereinafter referred to as compound (I)) and pharmacologically acceptable salts thereof are isomerized due to the presence of asymmetric carbon, etc. (R, S, ⁇ , ⁇ , enantiomer, diastereomer), optical isomers with optical activity (D, L, d, l, (+), ( ⁇ ) ), Polar isomers (high polarity, low polarity) by chromatographic separation, mixtures of these in any proportion, and racemic mixtures.
- compound (I) 2,3-dihydro-1H-inden-2-ylurea derivative of the present invention
- pharmacologically acceptable salts thereof are isomerized due to the presence of asymmetric carbon, etc. (R, S, ⁇ , ⁇ , enantiomer, diastereomer), optical isomers with optical activity (D, L, d, l, (+), ( ⁇ ) ), Polar is
- Halogen means fluoro, chloro, bromo and iodo.
- Alkyl having 1 to 6 carbon atoms represents a linear or branched saturated hydrocarbon group composed of 1 to 6 carbons, and “(one or more halogens, R 6 O— and / or (R 6 ) May be substituted with 2 N— ”), a part or all of the hydrogen atoms on the alkyl group are halogen, R 6 O— and / or (R 6 ) 2 N— (
- R 6 includes a group substituted with hydrogen or alkyl having 1 to 6 carbon atoms (which may be substituted with one or more halogen atoms), for example, methyl, ethyl, 1 -Propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2,2-dimethyl-1 -Propyl, trifluoromethyl, 2,2,2-trifluoroethyl, Pentafluor
- cycloalkyl having 3 to 8 carbon atoms represents a monocyclic or polycyclic saturated cyclic hydrocarbon group composed of 3 to 8 carbons, and includes “(1 to 3 each independently substituted with R 6. 1 to 3 methylenes constituting the ring may each independently be replaced by —O—, —S—, —C (O) — or —N (R 6 ) —.
- a carbon atom directly bonded to the benzene ring may be replaced by a nitrogen atom) ”, a group in which 1 to 3 hydrogen atoms on the alkyl group are substituted with R 6 1 to 3 methylenes constituting the ring are each directly bonded directly to a group in which —O—, —S—, —C (O) — or —N (R 6 ) — is substituted, and a phenyl group.
- the present invention includes all pharmacologically acceptable salts of the compound (I) of the present invention.
- a compound having a substituent capable of being salified can be converted into a corresponding salt by a known method.
- the acid to be added is preferably non-toxic and water-soluble, and includes inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid and phosphoric acid, acetic acid, lactic acid, citric acid, maleic acid, benzoic acid and oxalic acid. More preferred are organic carboxylic acids such as glutaric acid, malic acid, tartaric acid, fumaric acid, mandelic acid and succinic acid, or organic sulfonic acids such as methanesulfonic acid, p-toluenesulfonic acid and camphorsulfonic acid.
- inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid and phosphoric acid, acetic acid, lactic acid, citric acid, maleic acid, benzoic acid and oxalic acid. More preferred are organic carboxylic acids such as glutaric acid, malic acid, tartaric acid, fumaric acid, mandelic
- the base to be added is preferably a non-toxic and water-soluble base, and more preferably an inorganic base such as sodium hydroxide or potassium hydroxide.
- k is preferably 1 or 2, and more preferably 1.
- m is preferably 2 or 3, and more preferably 3.
- n is preferably 0 to 2.
- R 1 and R 2 are preferably hydrogen.
- each R 3 is independently preferably R 6 O— or (R 6 ) 2 N—, more preferably R 6 O—, and even more preferably hydroxy.
- each R 4 is independently substituted with alkyl having 1 to 6 carbon atoms (one or more halogen, R 6 O— and / or (R 6 ) 2 N—).
- a cycloalkyl having 3 to 8 carbon atoms (which may be substituted with 1 to 3 independent R 6 s , and each of 1 to 3 methylenes constituting the ring is independently -, -S-, -C (O)-or -N (R 6 )-may be substituted, and the carbon atom bonded to the benzene ring may be substituted with a nitrogen atom), R 6 O- , (R 6 ) 2 N— or halogen is preferred, methoxy, ethoxy, 2-propyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-2-butyl, pyrrolidino, piperidino, azepanyl, morpholino, bromo 2,2,2-trifluoro-1- Droxyethyl,
- each R 5 is preferably independently R 6 O— or halogen, more preferably hydroxy, methoxy, ethoxy, fluoro, chloro or bromo.
- R 3a is preferably R 6 O—, more preferably hydroxy.
- R 3b is preferably hydrogen.
- R 4a is preferably R 6 O—, more preferably methoxy or ethoxy, and further preferably methoxy.
- R 4b is an alkyl group having 3 to 6 carbon atoms or a cycloalkyl group having 3 to 8 carbon atoms (which may be substituted with 1 to 3 independent R 6 groups, each having 1 to 3 carbon atoms constituting the ring).
- Each of the methylenes may be independently replaced by —O—, —S—, —C (O) — or —N (R 6 ) —, and the carbon atom directly bonded to the benzene ring is a nitrogen atom Or a halogen, preferably 2-propyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-2-butyl, pyrrolidinyl, piperidinyl, azepanyl, morpholinyl or bromo. More preferred is -methyl-2-propyl.
- each R 5 is preferably independently R 6 O— or halogen, more preferably hydroxy, methoxy, ethoxy, fluoro, chloro or bromo.
- X is preferably hydroxy, amino, methylamino or dimethylamino, more preferably hydroxy.
- Examples of the compound (I) of the present invention include compounds shown in Table 1 represented by the general formula (Ib). In the table, the wavy line in the structural formula indicates that the position is substituted.
- the raw material compound when it has a hydroxyl group, it may be protected by a commonly used protecting group, and the target compound can be obtained by removing the protecting group as necessary after the reaction.
- the protecting group for the hydroxyl group include an alkyl group, a phenyl group, a triphenylmethyl group, an aralkyl group, an acyl group, and a substituted silyl group.
- the method for removing the protecting group is appropriately selected depending on the kind of the protecting group, and a known method, for example, a method described in PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (WILEY-INTERSCIENCE) can be used.
- the raw material compound may be used as a salt.
- the acid or base to be added include those similar to the above-mentioned salification of the compound (I) of the present invention.
- the compound (I) of the present invention obtained by the following production method can be isolated and purified by known means.
- Examples of the isolation and purification method include solvent extraction, recrystallization, and chromatography.
- each isomer can be obtained as a single compound by a known method.
- Y represents an alkyl group having 1 to 6 carbon atoms (which may be substituted with one or more halogen atoms) or an aryl group having 6 to 10 carbon atoms (which may be optionally substituted).
- the carbamate compound represented by the general formula (IV) can be synthesized by reacting the aniline derivative represented by the general formula (II) with the chloroformate represented by the general formula (III) in an appropriate solvent in the presence of a base.
- chloroformate examples include those having a leaving group that allows the ureation reaction in the second step to proceed smoothly, such as methyl chloroformate, ethyl chloroformate, chloroformate 2,2,2-trichloroethyl, chloroformate
- examples include phenyl, 4-chlorophenyl chloroformate, 4-nitrophenyl chloroformate, or 1-naphthyl chloroformate, with 2,2,2-trichloroethyl chloroformate or phenyl chloroformate being preferred.
- the amount of the above chloroformate used is preferably 0.5 to 5 moles, more preferably 0.8 to 3 moles per mole of the aniline derivative represented by the general formula (II).
- Examples of the coexisting base include alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate, alkali metal carbonates such as potassium carbonate and cesium carbonate, amines such as triethylamine, N, N-diisopropylethylamine and pyridine, Alkali metal alkoxides such as potassium tert-butoxide or hydrides of alkali metals such as sodium hydride can be mentioned, and sodium hydrogen carbonate, triethylamine or N, N-diisopropylethylamine is preferred.
- alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate
- alkali metal carbonates such as potassium carbonate and cesium carbonate
- amines such as triethylamine, N, N-diisopropylethylamine and pyridine
- Alkali metal alkoxides such as potassium tert-butoxide or hydrides of alkali metals such as sodium hydride
- the amount of base used is preferably 0.5 to 6 moles, more preferably 0.8 to 3 moles per mole of the aniline derivative represented by the general formula (II).
- the reaction solvent is usually appropriately selected from solvents that do not inhibit the reaction.
- ether solvents such as tetrahydrofuran (hereinafter THF), 1,4-dioxane, ethylene glycol dimethyl ether, dichloromethane, chloroform, 1,2-dichloroethane, and the like.
- Halogen solvents aromatic hydrocarbon solvents such as benzene and toluene, aprotic polar solvents such as N, N-dimethylformamide (hereinafter DMF) and dimethyl sulfoxide (hereinafter DMSO), and ketones such as acetone and methyl ethyl ketone
- DMF N, N-dimethylformamide
- DMSO dimethyl sulfoxide
- ketones such as acetone and methyl ethyl ketone
- the solvent include nitrile solvents such as acetonitrile and propionitrile, water, and mixed solvents thereof, and ether solvents are preferable.
- the concentration of the aniline derivative represented by the general formula (II) in the reaction solution is preferably 0.01 to 5 mol / L, more preferably 0.1 to 2 mol / L.
- the reaction temperature is preferably ⁇ 78 to 200 ° C., more preferably ⁇ 20 to 100 ° C.
- the reaction time is appropriately selected according to the reaction temperature and other conditions, but satisfactory results are usually obtained in about 10 to 30 hours.
- the urea compound represented by the general formula (Id) is a carbamate compound represented by the general formula (IV) and 2-amino-2,3-dihydro-1H— represented by the general formula (V) in an appropriate solvent in the presence of a base. It can be synthesized by reacting with an indene compound.
- Examples of the coexisting base include alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, trialkylamines such as triethylamine and N, N-diisopropylethylamine, and cyclic such as diazabicyclo [5.4.0] undecene.
- alkali metal hydroxides such as sodium hydroxide and potassium hydroxide
- trialkylamines such as triethylamine and N, N-diisopropylethylamine
- cyclic such as diazabicyclo [5.4.0] undecene.
- amidines or aromatic amines such as pyridine and N, N-dimethylaminopyridine, with trialkylamines being preferred.
- the amount of the base used in combination is preferably 0.5 to 10 mol, more preferably 0.8 to 5 mol, relative to 1 mol of the carbamate compound represented by the general formula (IV).
- the reaction solvent is appropriately selected from solvents that do not normally inhibit the reaction.
- ether solvents such as THF, 1,4-dioxane, ethylene glycol dimethyl ether, halogen solvents such as dichloromethane, chloroform, 1,2-dichloroethane, benzene, and the like.
- Aromatic hydrocarbon solvents such as toluene, aprotic polar solvents such as DMF and DMSO, ketone solvents such as acetone and methyl ethyl ketone, nitrile solvents such as acetonitrile and propionitrile, water or a mixed solvent thereof
- ether solvents, nitrile solvents, or mixed solvents thereof with water are preferable.
- the concentration of the carbamate compound represented by the general formula (IV) in the reaction solution is preferably 0.01 to 5 mol / L, and more preferably 0.1 to 2 mol / L.
- the reaction temperature is preferably ⁇ 20 to 200 ° C., more preferably 0 to 150 ° C.
- the reaction time is appropriately selected according to the reaction temperature and other conditions, but satisfactory results are usually obtained in about 30 minutes to 48 hours.
- the aniline derivatives represented by the general formula (IX) having a 2,2,2-trifluoro-1-hydroxyethyl group can be produced by the method shown in Scheme 2.
- the nitro compound represented by the general formula (VII) can be synthesized by reacting the benzaldehyde derivative represented by the general formula (VI) with a nitrating agent in an appropriate solvent.
- Examples of the benzaldehyde derivative represented by the general formula (VI) include a commercially available compound or a derivative from a commercially available compound.
- Examples of methods for inducing commercially available products include Bioorganic & Medicinal Chemistry (2008, Vol. 16, No. 15, p. 7193-7205) and Synthesis (1998, Vol. 7, p. 1029-1032). The method described is mentioned.
- nitrating agent examples include nitronium salts such as nitronium cation or nitronium tetrafluoroborate generated in the reaction system by a combination of nitric acid and sulfuric acid, nitric acid and acetic anhydride, etc. preferable.
- the amount of the nitrating agent used is preferably 0.5 to 5 mol, more preferably 0.8 to 3 mol, per 1 mol of the benzaldehyde derivative represented by the general formula (VI).
- reaction solvent a solvent that does not inhibit the reaction.
- ester solvents such as ethyl acetate and n-propyl acetate
- nitrile solvents such as acetonitrile and propionitrile
- THF 1,4-dioxane
- ether solvents such as dimethyl ether
- halogen solvents such as dichloromethane, chloroform, 1,2-dichloroethane, and mixed solvents thereof
- ester solvents or nitrile solvents are preferable.
- the concentration of the benzaldehyde derivative represented by the general formula (VI) in the reaction solution is preferably 0.01 to 5 mol / L, and more preferably 0.05 to 2 mol / L.
- the reaction temperature is preferably ⁇ 78 to 50 ° C., more preferably ⁇ 40 to 30 ° C.
- the reaction time is appropriately selected according to the reaction temperature and other conditions, but satisfactory results are usually obtained in about 30 minutes to 6 hours.
- the trifluoroethanol derivative represented by the general formula (VIII) is obtained by reacting the benzaldehyde derivative represented by the general formula (VII) with a trifluoromethylating agent in an appropriate solvent in the presence of a fluoride salt as necessary. Can be synthesized.
- fluoride salt to be coexisted examples include alkali metal salts such as sodium fluoride and potassium fluoride, and ammonium salts such as tetramethylammonium fluoride and tetra n-butylammonium fluoride. Ammonium salts are preferred.
- the amount of the fluoride salt used is preferably 0.01 to 2 mol, more preferably 0.05 to 1 mol, per 1 mol of the benzaldehyde derivative represented by the general formula (VII).
- trifluoromethylating agent examples include trifluoromethyl iodide and trimethyl (trifluoromethyl) silane, and trimethyl (trifluoromethyl) silane is preferable.
- the amount of the trifluoromethylating agent used is preferably 0.5 to 10 mol, more preferably 0.8 to 5 mol, per 1 mol of the benzaldehyde derivative represented by the general formula (VII).
- reaction solvent a solvent that usually does not inhibit the reaction is appropriately selected.
- an ether solvent such as THF, 1,4-dioxane, ethylene glycol dimethyl ether, an aromatic hydrocarbon solvent such as benzene, toluene, or a mixed solvent thereof.
- ether solvents are preferred.
- the concentration of the benzaldehyde derivative represented by the general formula (VII) in the reaction solution is preferably 0.001 to 5 mol / L, and more preferably 0.05 to 1 mol / L.
- the reaction temperature is preferably ⁇ 78 to 50 ° C., more preferably ⁇ 30 to 30 ° C.
- the reaction time is appropriately selected according to the reaction temperature and other conditions, but satisfactory results are usually obtained in about 30 minutes to 12 hours.
- the aniline derivative represented by the general formula (IX) can be synthesized by reducing the nitro group of the nitro compound represented by the general formula (VIII) in an appropriate solvent.
- Examples of the reduction method include catalytic hydrogenation or one-electron reduction.
- Catalytic hydrogenation examples of the metal catalyst to be used include palladium / activated carbon, palladium hydroxide / activated carbon, and platinum oxide, and palladium / activated carbon is preferable.
- the amount of the metal catalyst used is preferably 0.5 to 200% by weight, more preferably 5 to 100% by weight, based on 1 mole of the nitro compound represented by the general formula (VIII).
- the hydrogen gas pressure is preferably 1 to 10 atm, and more preferably 1 to 3 atm.
- reaction solvent a solvent that does not normally inhibit the reaction is appropriately selected.
- alcohol solvents such as methanol, ethanol and 2-propanol
- ester solvents such as ethyl acetate and n-propyl acetate, THF, 1,4-dioxane and the like.
- Ether solvents such as ethylene glycol dimethyl ether
- halogen solvents such as dichloromethane, chloroform, 1,2-dichloroethane, water, or a mixed solvent thereof.
- Alcohol solvents or ester solvents are preferred.
- the concentration of the nitro compound represented by the general formula (VIII) in the reaction solution is preferably 0.001 to 5 mol / L, more preferably 0.05 to 2 mol / L.
- the reaction temperature is preferably 0 to 100 ° C, more preferably 10 to 60 ° C.
- the reaction time is appropriately selected according to the reaction temperature and other conditions, but satisfactory results are usually obtained in about 30 minutes to 48 hours.
- Examples of the reducing agent to be used include simple metals such as iron, nickel and tin, and metal chlorides such as iron chloride and tin chloride. Iron is preferred.
- the amount of the reducing agent used is preferably 1 to 20 mol, more preferably 1 to 10 mol, per 1 mol of the nitro compound represented by the general formula (VIII).
- An activator is preferably allowed to coexist in the reaction solution.
- the activator include inorganic acids such as hydrochloric acid and sulfuric acid, and ammonium salts such as ammonium chloride, with ammonium salts being preferred.
- the amount of the activator is preferably 1 to 20 mol, and more preferably 1 to 10 mol, relative to 1 mol of the nitro compound represented by the general formula (VIII).
- reaction solvent a solvent that does not normally inhibit the reaction is appropriately selected.
- alcohol solvents such as methanol, ethanol, 2-propanol, ether solvents such as THF, 1,4-dioxane, ethylene glycol dimethyl ether, water or the like
- ether solvents such as THF, 1,4-dioxane, ethylene glycol dimethyl ether, water or the like
- a mixed solvent of an alcohol solvent and water, a mixed solvent of an ether solvent and water, an alcohol solvent, an ether solvent and a mixed solvent of water are preferable.
- the concentration of the nitro compound represented by the general formula (VIII) in the reaction solution is preferably 0.005 to 5 mol / L, more preferably 0.1 to 2 mol / L.
- the reaction temperature is preferably 10 to 150 ° C, more preferably 50 to 120 ° C.
- the reaction time is appropriately selected according to the reaction temperature and other conditions, but satisfactory results are usually obtained in about 30 minutes to 24 hours.
- the aniline derivative represented by the general formula (IX) can obtain a desired isomer by a generally used method (optical resolution, diastereomer resolution, etc.) as necessary.
- the aniline derivatives represented by the general formula (XI) having a 2,2,2-trifluoro-1-hydroxyethyl group and a cyclic amino substituent can be produced by the method shown in Scheme 3. it can.
- R 4b ′ represents bromo or iodo
- the compound represented by the general formula (X) containing A represents a cyclic secondary amine.
- the cyclic amino-substituted aniline derivative represented by the general formula (XI) is represented by the general formula (X) in the presence of a metal catalyst, a ligand and a base in the presence of a metal catalyst, a ligand and a base. It can synthesize
- metal catalyst examples include palladium catalysts such as tris (dibenzylideneacetone) dipalladium, palladium acetate and tetrakis (triphenylphosphine) palladium, and copper catalysts such as copper oxide and copper iodide. Is preferred.
- palladium catalysts such as tris (dibenzylideneacetone) dipalladium, palladium acetate and tetrakis (triphenylphosphine) palladium
- copper catalysts such as copper oxide and copper iodide. Is preferred.
- the amount of the metal catalyst used is preferably 0.001 to 1 mol, more preferably 0.01 to 0.5 mol, based on 1 mol of the aniline derivative represented by the general formula (IXa).
- the ligand of the metal catalyst is appropriately selected according to the metal catalyst, and examples of the ligand of the palladium catalyst include triphenylphosphine, 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl, Examples include phosphine derivatives such as 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene, and 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene is preferable. Examples of the copper catalyst ligand include amino acid derivatives such as proline and N, N-dimethylglycine.
- the amount of the ligand used is preferably 0.001 to 1 mol, and more preferably 0.01 to 0.5 mol, per 1 mol of the aniline derivative represented by the general formula (IXa).
- Examples of the base to be coexisted include alkali metal carbonates such as sodium carbonate and potassium carbonate, alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate, alkali metal phosphates such as sodium phosphate and potassium phosphate, or Alkali metal hydrogen phosphates such as sodium hydrogen phosphate, potassium hydrogen phosphate, sodium dihydrogen phosphate, and potassium dihydrogen phosphate are exemplified, and alkali metal carbonates are preferable.
- the amount of the base used is preferably 1 to 10 mol, more preferably 1 to 5 mol, relative to 1 mol of the aniline derivative represented by the general formula (IXa).
- the amount of the cyclic secondary amine used is preferably 1 to 20 moles, more preferably 1 to 10 moles per mole of the aniline derivative represented by the general formula (IXa).
- reaction solvent a solvent that does not normally inhibit the reaction is appropriately selected, and examples thereof include ether solvents such as THF, 1,4-dioxane, ethylene glycol dimethyl ether, and aprotic polar solvents such as DMF and DMSO. Protic polar solvents are preferred.
- the concentration of the aniline derivative represented by the general formula (IXa) in the reaction solution is preferably 0.005 to 5 mol / L, and more preferably 0.01 to 2 mol / L.
- the reaction temperature is preferably 0 to 200 ° C, more preferably 30 to 150 ° C.
- the reaction time is appropriately selected according to the reaction temperature and other conditions, but satisfactory results are usually obtained in about 1 to 48 hours.
- R 4b ′ represents bromo or iodo
- the compound represented by General Formula (XIII) containing B represents a cycloalkanone.
- the hydroxycycloalkane derivative represented by the general formula (XIV) is an intermediate obtained by allowing a base to act on the halogenated aryl compound represented by the general formula (XII) in an appropriate solvent. It can synthesize
- Examples of the base used include alkyl lithiums such as n-butyl lithium and sec-butyl lithium, alkyl Grignard reagents such as isopropyl magnesium chloride and cyclohexyl magnesium chloride, and alkali metal alkoxides such as potassium tert-butoxide. Is preferred.
- the amount of the base used is preferably 0.5 to 10 mol, more preferably 1 to 5 mol, relative to 1 mol of the halogenated aryl compound represented by the general formula (XII).
- the amount of the cycloalkanone is preferably 1 to 20 moles, more preferably 1 to 5 moles per mole of the halogenated aryl compound represented by the general formula (XII).
- reaction solvent a solvent that normally does not inhibit the reaction is appropriately selected, and examples thereof include ether solvents such as THF, 1,4-dioxane, and ethylene glycol dimethyl ether, and THF is preferable.
- the concentration of the halogenated aryl compound represented by the general formula (XII) in the reaction solution is preferably 0.01 to 5 mol / L, and more preferably 0.05 to 3 mol / L.
- the reaction temperature is preferably ⁇ 100 to 50 ° C., more preferably ⁇ 80 to 20 ° C.
- the reaction time is appropriately selected according to the reaction temperature and other conditions, but satisfactory results are usually obtained in about 30 minutes to 12 hours.
- the methylcycloalkane derivative represented by the general formula (XV) can be synthesized by reacting the hydroxycycloalkane derivative represented by the general formula (XIV) with a methylating agent in the presence of a Lewis acid in an appropriate solvent.
- Lewis acid to coexist examples include metal chlorides such as aluminum chloride, titanium chloride or zinc chloride, with titanium chloride being preferred.
- the amount of the Lewis acid used is preferably 0.5 to 10 mol, more preferably 1 to 5 mol, per 1 mol of the hydroxycycloalkane derivative represented by the general formula (XIV).
- methylating agent examples include methyllithium, methylmagnesium bromide, and dimethylzinc, and dimethylzinc is preferable.
- the amount of the methylating agent used is preferably 1 to 20 mol, and more preferably 1 to 10 mol, per 1 mol of the hydroxycycloalkane derivative represented by the general formula (XIV).
- reaction solvent a solvent that does not normally inhibit the reaction is appropriately selected.
- halogen solvents such as dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride or ethers such as THF, 1,4-dioxane, ethylene glycol dimethyl ether, etc.
- the solvent include halogen solvents.
- the concentration of the hydroxycycloalkane derivative represented by the general formula (XIV) in the reaction solution is preferably 0.01 to 5 mol / L, and more preferably 0.05 to 2 mol / L.
- the reaction temperature is preferably ⁇ 100 to 0 ° C., more preferably ⁇ 90 to ⁇ 30 ° C.
- the reaction time is appropriately selected according to the reaction temperature and other conditions, but satisfactory results are usually obtained in about 30 minutes to 6 hours.
- the benzaldehyde derivative represented by the general formula (XVI) can be synthesized by reacting the methylcycloalkane derivative represented by the general formula (XV) with a formylating agent in the presence of a Lewis acid in an appropriate solvent.
- Lewis acid to be coexisted examples include metal chlorides such as aluminum chloride, titanium chloride or zinc chloride, with titanium chloride being preferred.
- the amount of the Lewis acid used is preferably 0.5 to 10 mol, more preferably 1 to 5 mol, per 1 mol of the methylcycloalkane derivative represented by the general formula (XV).
- dichloromethyl methyl ether is preferable.
- the amount of the formylating agent used is preferably 1 to 20 mol, more preferably 1 to 10 mol, per 1 mol of the methylcycloalkane derivative represented by the general formula (XV).
- reaction solvent a solvent that does not normally inhibit the reaction is appropriately selected.
- halogen solvents such as dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride or ethers such as THF, 1,4-dioxane, ethylene glycol dimethyl ether, etc.
- the solvent include halogen solvents.
- the concentration of the methylcycloalkane derivative represented by the general formula (XV) in the reaction solution is preferably 0.01 to 5 mol / L, more preferably 0.05 to 2 mol / L.
- the reaction temperature is preferably ⁇ 100 to 0 ° C., more preferably ⁇ 90 to ⁇ 30 ° C.
- the reaction time is appropriately selected according to the reaction temperature and other conditions, but satisfactory results are usually obtained in about 30 minutes to 6 hours.
- an optically active acid is used as necessary according to a method described in the literature (Tetrahedron: Asymmetry, 1995, Vol. 6, No. 7, p. 1535-1538, etc.). By performing optical resolution, it can be obtained as an amine of an optically active substance.
- optically active acid examples include carboxylic acids such as lactic acid, tartaric acid, 2-phenylpropionic acid and mandelic acid, acidic amino acids such as glutamic acid and aspartic acid, and sulfonic acids such as camphorsulfonic acid, depending on the compound. Satisfactory results can be obtained.
- the effect of the compound (I) of the present invention or a pharmacologically acceptable salt thereof on allergic dermatitis is determined by a model I allergic dermatitis (for example, Inflamm. Res., 1998, Vol. 47, p. 506-511) and type IV allergic dermatitis model (see, for example, Int. Arch. Allergy. Appl. Immunol., 1990, Vol. 92, p. 356-360). It can be evaluated by the action of suppressing the swelling reaction of the skin induced by the antigen. It is known that the dermatitis reaction observed in this model is similar to the swelling reaction observed at the time of antigen application in human allergic dermatitis patients. The method is also used as an animal model for atopic dermatitis.
- Compound (I) of the present invention or a pharmacologically acceptable salt thereof is an allergic dermatitis induced by an antigen, more specifically, diffuse neurodermatitis, atopic eczema, atopic neurodermatitis , Benie eruption, acute infant eczema, flexion eczema, extremity eczema, infant atopic eczema, infant dry eczema, infant eczema, adult atopic dermatitis, endogenous eczema, infant dermatitis or chronic infant eczema Can be used.
- an antigen more specifically, diffuse neurodermatitis, atopic eczema, atopic neurodermatitis , Benie eruption, acute infant eczema, flexion eczema, extremity eczema, infant atopic eczema, infant dry eczema, infant eczema, adult atopic
- antigens used here include mite allergens (such as white mite, mushroom mites), food allergens (egg white, milk, wheat, soybeans, rice, corn, sesame, buckwheat), pollen allergens (ragweed, mugwort, ginkgo biloba, harkaya, Camouflage, Drosophila, Papilio elegans, reeds, etc., fungal allergens (Candida, Penicillium, Cladosporium, Aspergillus, Arterinalia, etc.), animal epithelial allergens (cats, dogs) or hapten antigens (2,4-dinitrofluorbenzene) (hereinafter referred to as DNFB) , DNP, TNP, etc.).
- mite allergens such as white mite, mushroom mites
- food allergens egg white, milk, wheat, soybeans, rice, corn, sesame, buckwheat
- pollen allergens
- the compound (I) of the present invention or a pharmacologically acceptable salt thereof is a symptom associated with allergic dermatitis, more specifically, erythema, papule, scales, skin formation, lichenification, dryness. (Dry skin), pruritus, xeroderma, cheilitis, pore keratinization, blackening of the eyelids, facial pallor, white rash, food intolerance, white skin illness, delayed pallor reaction, etc. be able to.
- TNBS 2,4,6-trinitrobenzenesulfonic acid
- DSS dextran sulfate sodium
- the TNBS-induced colitis model is known to be similar to human Crohn's disease, and the DSS-induced chronic colitis model is known to be similar to human ulcerative colitis (eg, Gastroenterology, 2002, 37th). Volume, pages 409-417).
- the compound (I) of the present invention or a pharmacologically acceptable salt thereof can be used to improve inflammatory bowel disease, more specifically, Crohn's disease or ulcerative colitis.
- the compound (I) of the present invention or a pharmacologically acceptable salt thereof is a symptom associated with inflammatory bowel disease, more specifically, diarrhea, abdominal pain, fever, bloody stool, mucous stool, anorexia, body weight. It can be used to improve reduction, anemia, vomiting, melena, abdominal mass or general malaise.
- the effect of the compound (I) of the present invention or a pharmacologically acceptable salt thereof on pain is an inflammatory pain model (see, for example, Anesth. Analg., 2009, Vol. 108, pp. 1680-1687) or Neuropathic pain models represented by the Bennett model and the Chung model (see, for example, Pain, 1988, 33, p. 87-107 and Pain, 1992, 50, p. 355-363), etc.
- the method described in the literature can be used to evaluate the inhibitory effect on pain induced by administration of a inflammatory substance (eg, carrageenan) or surgical nerve injury.
- a inflammatory substance eg, carrageenan
- the compound (I) of the present invention or a pharmacologically acceptable salt thereof can be used for improving pain, more specifically, inflammatory pain and neuropathic pain.
- inflammatory pain and neuropathic pain include headache, toothache, chest pain, abdominal pain, arthritic pain, trigeminal neuralgia, sciatica, diabetic neuropathic pain, cancer neuropathic pain, HIV neuropathic pain. , Postherpetic neuralgia or spinal cord injury.
- the compound (I) of the present invention or a pharmacologically acceptable salt thereof can be used as a pharmaceutical for mammals (eg, mouse, rat, hamster, rabbit, cat, dog, monkey, cow, sheep, human). it can.
- mammals eg, mouse, rat, hamster, rabbit, cat, dog, monkey, cow, sheep, human. it can.
- the free form or a pharmacologically acceptable salt thereof is used as it is or with a pharmaceutically acceptable carrier, and used for the purpose of systemic action or local action. be able to.
- Examples of the dosage form include oral preparations such as tablets, capsules, granules, fine granules, powders, syrups, and liquids, or injections, inhalants, suppositories, nasal drops, eye drops, lotions, Examples include parenteral preparations such as ointments, creams, patches or patches.
- Preparation of a preparation containing the compound (I) of the present invention or a pharmacologically acceptable salt thereof can be performed according to a known production method generally used in the pharmaceutical field.
- excipients, binders, lubricants, disintegrating agents, sweeteners, surfactants, suspending agents, emulsifiers, pH adjusters or bases generally used in the pharmaceutical field. Etc. can be contained.
- excipient examples include lactose, sucrose, sucrose, sorbitol, mannitol, erythritol, crystalline cellulose, corn starch, gelatin, dextran, and low-substituted hydroxypropylcellulose.
- binder examples include starch, gum arabic, gelatin, tragacanth, carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, sodium alginate or glycerin.
- lubricant examples include magnesium stearate, calcium stearate, stearic acid, sucrose fatty acid ester, light anhydrous silicic acid, and talc.
- disintegrant examples include starch, crystalline cellulose, low-substituted hydroxypropyl cellulose, croscarmellose sodium, crospovidone, carmellose calcium, or partially pregelatinized starch.
- sweetener examples include glucose, fructose, invert sugar, sorbitol, xylitol, glycerin, and simple syrup.
- surfactant examples include sodium lauryl sulfate, polysorbate 80, sorbitan monofatty acid ester, and polyoxyl 40 stearate.
- suspending agent examples include gum arabic, sodium alginate, sodium carboxymethyl cellulose, methyl cellulose, and bentonite.
- emulsifier examples include gum arabic, tragacanth, gelatin, and polysorbate 80.
- Examples of the pH adjuster include phosphoric acid, tartaric acid, citric acid, glutamic acid, sodium hydroxide, and magnesium oxide.
- Examples of the base include petrolatum, plastibase, polyethylene glycol, polyethylene oxide, polypropylene glycol, glycerin, liquid paraffin, hydrophilic ointment and water-absorbing ointment.
- the content of the compound (I) of the present invention or a pharmacologically acceptable salt thereof as an active ingredient in the above preparation is preferably 0.001 to 90% by weight, more preferably 0.01 to 70% by weight.
- the dose of the compound (I) of the present invention or a pharmacologically acceptable salt thereof is appropriately selected according to the symptoms, age, weight, sex, administration method, etc. of the patient.
- the amount is preferably 0.01 mg to 25 g, more preferably 0.1 mg to 10 g, and in the case of an oral preparation, 0.1 mg to 50 g is preferable, and 1 mg to 20 g is more preferable.
- the concentration of the active ingredient administered to the affected area in one or several divided doses is preferably 0.0001 to 10%, more preferably 0.001 to 5%.
- the compound (I) of the present invention or a pharmacologically acceptable salt thereof may be used alone, but for the treatment or prevention of diseases, for the reduction or suppression of symptoms, the prevention or treatment effect complementation or It may be used in combination with or in combination with other drugs for enhancement or for reduction of dosage.
- drugs examples include, for example, steroids (prednisolone, methylprednisolone, hydrocortisone, betamethasone, budesonide, etc.), immunosuppressants (mercaptopurine, methotrexate, azathioprine, cyclosporine, tacrolimus, etc.), petrolatum, urea ointment, Zinc flower ointment, antihistamine (such as chlorpheniramine), antiallergic agent (sodium cromoglycate), Th2 cytokine inhibitor (such as suplatast), NF ⁇ B decoy DNA, adhesion molecule inhibitor, active oxygen scavenger, active oxygen production inhibitor, Antibiotics (such as metronidazole), antibacterial agents, aminosalicylic acid preparations (such as salazopyrine and mesalazine) and their derivatives, prostaglandin synthase inhibitors, proteolytic enzyme inhibitors (such as urin
- Example 1 (5-tert-butyl-3- (hydroxymethyl) -2-methoxyphenyl) -3-((1S, 2R) -1-hydroxy-2,3-dihydro-1H-inden-2-yl) urea Synthesis of (Compound 1) [First step] Synthesis of 5-tert-butyl-2-methoxy-3-nitrobenzaldehyde A solution of 5-tert-butyl-2-hydroxybenzaldehyde (7.71 g, 43.3 mmol) in acetonitrile (216 mL) was cooled to ⁇ 40 ° C. Nitrotetrafluoroborate (7.47 g, 56.2 mmol) was added.
- Example 2 1- (5-tert-butyl-3- (hydroxymethyl) -2-methoxyphenyl) -3-((1S, 2R) -4-fluoro-1-hydroxy-2,3-dihydro-1H-indene-2 -Ill) Synthesis of urea (compound 3) 2,2,2-trichloroethyl 5-tert-butyl-3- (hydroxymethyl) -2-methoxyphenylcarbamate (0.100 g, 0.260 mmol) and (1S, 2R) -2-amino-4-fluoro -2,3-dihydro-1H-inden-1-ol.L-tartrate (0.091 g, 0.286 mmol) was used to carry out the same reaction as in Example 1 [5th step] to give the title compound 0.034 g (yield 32%) was obtained.
- Example 4 (3- (1-Amino-2,2,2-trifluoroethyl) -5-tert-butyl-2-methoxyphenyl) -3-((1S, 2R) -1-hydroxy-2,3- Synthesis of dihydro-1H-inden-2-yl) urea (compound 47a, compound 47b) [First step] Synthesis of tert-butyl 1- (5-tert-butyl-2-methoxy-3-nitrophenyl) -2,2,2-trifluoroethylcarbamate 1- (5-tert-butyl-2-methoxy-3- To a solution of nitrophenyl) -2,2,2-trifluoroethanol (0.500 g, 1.62 mmol) in acetonitrile (13 mL) was added concentrated sulfuric acid 1.30 mL (24.4 mmol), and the mixture was heated to reflux for 2 hours.
- reaction solution was allowed to cool, and the reaction solution was added to a saturated aqueous sodium hydrogen carbonate solution to adjust the pH to 8.
- the aqueous layer was extracted with ethyl acetate, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and filtered, and then the solvent was evaporated under reduced pressure.
- triethylamine (0.32 mL, 2.31 mmol)
- ditert-butyl dicarbonate 0.510 g, 2.31 mmol
- 4- (dimethylamino) pyridine (0. 024 g) was added and stirred at room temperature for 4 hours.
- Example 7 1- (5-tert-butyl-2-methoxy-3-((R) -2,2,2-trifluoro-1-hydroxyethyl) phenyl) -3- (cis-4-fluoro-1-hydroxy- Synthesis of 2,3-dihydro-1H-inden-2-yl) urea (compound 50a, compound 50b) (R) -2,2,2-Trichloroethyl 5-tert-butyl-2-methoxy-3- (2,2,2-trifluoro-1-hydroxyethyl) phenylcarbamate (0.203 g, 0.449 mmol) ) And ( ⁇ ) -cis-2-amino-4-fluoro-2,3-dihydro-1H-inden-1-ol (0.090 g, 0.538 mmol) and Example 3 [Step 4] and By performing the same reaction, 0.081 g (yield 39%) of the title compound 50a on the low polarity side and 0.075
- Example 9 1- (5-tert-butyl-2-methoxy-3- (2,2,2-trifluoro-1-hydroxyethyl) phenyl) -3-((1S, 2R) -1-hydroxy-4-methoxy- Synthesis of 2,3-dihydro-1H-inden-2-yl) urea (compound 52a, compound 52b) 2,2,2-trichloroethyl 5-tert-butyl-2-methoxy-3- (2,2,2-trifluoro-1-hydroxyethyl) phenylcarbamate (0.240 g, 0.530 mmol) and (1S , 2R) -2-Amino-4-methoxy-2,3-dihydro-1H-inden-1-ol (0.114 g, 0.636 mmol) was used for the same reaction as in Example 3 [Step 4]. As a result, 0.113 g (yield 44%) of the title compound 52a on the low polarity side and 0.110 g (43% yield
- Example 12 1- (5-tert-butyl-2-methoxy-3-((R) -2,2,2-trifluoro-1-hydroxyethyl) phenyl) -3- (cis-6-fluoro-1-hydroxy- Synthesis of 2,3-dihydro-1H-inden-2-yl) urea (compound 60a, compound 60b) (R) -2,2,2-Trichloroethyl 5-tert-butyl-2-methoxy-3- (2,2,2-trifluoro-1-hydroxyethyl) phenylcarbamate (0.241 g, 0.532 mmol) ) And ( ⁇ ) -cis-2-amino-6-fluoro-2,3-dihydro-1H-inden-1-ol (0.080 g, 0.479 mmol) and Example 3 [Step 4] and By performing the same reaction, 0.040 g (yield 16%) of the title compound 60a on the low polarity side and 0.043
- Example 15 1- (5-tert-butyl-2-methoxy-3-((R) -2,2,2-trifluoro-1-hydroxyethyl) phenyl) -3- (cis-1-hydroxy-7-methoxy- Synthesis of 2,3-dihydro-1H-inden-2-yl) urea (compound 67a, compound 67b) (R) -2,2,2-Trichloroethyl 5-tert-butyl-2-methoxy-3- (2,2,2-trifluoro-1-hydroxyethyl) phenylcarbamate (0.250 g, 0.552 mmol) ) And ( ⁇ ) -cis-2-amino-7-methoxy-2,3-dihydro-1H-inden-1-ol (0.129 g, 0.720 mmol) and Example 3 [Step 4] and By performing the same reaction, 0.086 g (yield 32%) of the title compound 67a on the low polarity side and
- Example 16 1- (5-tert-butyl-2-methoxy-3-((R) -2,2,2-trifluoro-1-hydroxyethyl) phenyl) -3- (cis-1,7-dihydroxy-2, Synthesis of 3-dihydro-1H-inden-2-yl) urea (compound 68a, compound 68b) (R) -2,2,2-Trichloroethyl 5-tert-butyl-2-methoxy-3- (2,2,2-trifluoro-1-hydroxyethyl) phenylcarbamate (0.136 g, 0.300 mmol) ) And ( ⁇ ) -cis-2-amino-2,3-dihydro-1H-indene-1,7-diol (0.052 g, 0.315 mmol) in the same manner as in Example 4 [Step 4] By performing the reaction, 0.033 g (yield 23%) of the title compound 68a on the low polarity side and
- Example 18 1- (5-tert-butyl-2-methoxy-3-((R) -2,2,2-trifluoro-1-hydroxyethyl) phenyl) -3- (cis-1-methoxy-2,3- Synthesis of dihydro-1H-inden-2-yl) urea (compound 79a, compound 79b) (R) -2,2,2-Trichloroethyl 5-tert-butyl-2-methoxy-3- (2,2,2-trifluoro-1-hydroxyethyl) phenylcarbamate (0.200 g, 0.442 mmol) ) And ( ⁇ ) -cis-1-methoxy-2,3-dihydro-1H-indene-2-amine (0.094 g, 0.576 mmol), and the same reaction as in Example 3 [Step 4] was performed. As a result, 0.087 g (yield 42%) of the title compound 79a on the low polarity side and 0.088
- Example 23 1-((1S, 2R) -4-fluoro-1-hydroxy-2,3-dihydro-1H-inden-2-yl) -3- (2-methoxy-5- (pyrrolidin-1-yl) -3 Synthesis of — (2,2,2-trifluoro-1-hydroxyethyl) phenyl) urea (compound 93a, compound 93b) 2,2,2-trichloroethyl 2-methoxy-5- (pyrrolidin-1-yl) -3- (2,2,2-trifluoro-1-hydroxyethyl) phenylcarbamate (0.169 g, 0.364 mmol) ) And (1S, 2R) -2-amino-4-fluoro-2,3-dihydro-1H-inden-1-ol.L-tartrate (0.127 g, 0.400 mmol) were used in Example 3 [ The same reaction as in Step 4] was carried out to obtain 0.045 g (yield 26
- Example 25 1- (5- (azepan-1-yl) -2-methoxy-3- (2,2,2-trifluoro-1-hydroxyethyl) phenyl) -3-((1S, 2R) -1-hydroxy- Synthesis of 2,3-dihydro-1H-inden-2-yl) urea (compound 102a, compound 102b) [First step] Synthesis of 1- (3-amino-5- (azepan-1-yl) -2-methoxyphenyl) -2,2,2-trifluoroethanol 1- (3-amino-5-bromo-2-methoxyphenyl) -2,2,2-trifluoroethanol (0.600 g, 2.00 mmol) and hexamethyleneimine (0.298 g, 3.00 mmol) are used to carry out the same reaction as in Example 20 [first step]. Gave 0.435 g (68% yield) of the title compound.
- reaction solution is diluted with ethyl acetate, the organic layer is washed with water and then with saturated brine, dried over anhydrous sodium sulfate, filtered, and then the solvent is distilled off under reduced pressure to obtain 0.719 g of a crude product containing the title compound. It was.
- a 100% DMSO solution of a test compound and a p38 ⁇ / SAPK2a solution (final concentration 1.5 nM) (Invitrogen) were added to a 384 well plate, followed by incubation at room temperature in the dark for 1 hour. Thereafter, ATP (final concentration: 100 ⁇ M) as a phosphate donor and biotinylated ATF2 (final concentration: 30 nM) (upstate) as a substrate were added, and the mixture was allowed to react for 1 hour in the dark at room temperature (final concentration of DMSO was 0. 25%).
- the compound (I) of the present invention showed a significantly higher p38 MAPK inhibitory activity than the comparative control compound.
- LPS (0111: B4, SIGMA) was intraperitoneally administered to BALB / c mice (male, 7-9 weeks old, Charles River, Japan) at a dose of 1 mg / kg.
- An ELISA Development System (R & D System) was used for the measurement of TNF- ⁇ in serum.
- test compound was dissolved in DMSO (final concentration 2%), then dissolved in a 27% aqueous solution of 2-hydroxypropyl- ⁇ -cyclodextrin (hereinafter HP- ⁇ -CD, Nippon Shokuhin Kako), and 30 minutes before administration of LPS 50 mg / kg was orally administered.
- HP- ⁇ -CD 2-hydroxypropyl- ⁇ -cyclodextrin
- HP- ⁇ -CD 2-hydroxypropyl- ⁇ -cyclodextrin
- Comparative Compound 3 was used as a comparative control compound.
- the inhibition rate of TNF ⁇ production by Comparative Compound 3 was 17.0%.
- the compound (I) of the present invention showed significantly higher oral activity than the comparative control compound.
- C max represents the maximum plasma concentration
- AUC 0- ⁇ represents the area under the curve of the plasma compound concentration up to infinity after compound administration.
- the compound (I) of the present invention showed significantly higher C max and AUC 0- ⁇ than the respective comparative control compounds, and showed excellent pharmacokinetics upon oral administration.
- the compound (I) of the present invention had a lower intrinsic clearance value than the comparative control compound, and thus showed excellent metabolic stability.
- HepG2 cells which are a human liver cancer-derived cell line, were mixed with a test compound and HCS Lipid TOX Green Phospholipidosis Detection Reagent (Invitrogen), which was a phospholipid staining solution, and cultured at 37 ° C. for 48 hours in the presence of 5% CO 2 . The culture supernatant after the culture was removed, and Hoechst 33258 (Invitrogen), which is a nucleic acid staining solution, was added, followed by reaction at room temperature for 20 minutes in the dark.
- HCS Lipid TOX Green Phospholipidosis Detection Reagent Invitrogen
- Hoechst 33258 which is a nucleic acid staining solution
- the fluorescence intensity was measured with a microplate analyzer (Fusion- ⁇ , Packard), and FLA (a relative value when Amiodarone hydrochloride (10 ⁇ M) as 1) was calculated by the following equation was calculated. .
- FLA a relative value when Amiodarone hydrochloride (10 ⁇ M) as 1
- the test compound was dissolved in DMSO and used, and added to the cells so that the final concentration of DMSO was 1%.
- the compound 46b described in the Examples was determined to be negative because the FLA was less than 1 even at a maximum concentration of 10 ⁇ M.
- Comparative compound 4c which is a comparative control compound, was evaluated by partially modifying the method described in Cell Biology and Toxology (2003, Vol. 19, p. 161-176).
- U937 cells which are a human monocyte-derived cell line, and a test compound were mixed and cultured at 37 ° C. for 48 hours in the presence of 5% CO 2 .
- the cultured cell suspension was replaced with a PBS solution containing Nile red (Invitrogen), which is a phospholipid staining solution, and allowed to react at room temperature for 10 minutes in the dark. After centrifugal washing with PBS solution, fluorescence intensity (excitation wavelength: 488 nm, detection range: 515-545 nm) was measured with a flow cytometer (Becton Dickinson).
- Valproic acid (300 ⁇ M) was used as a negative control substance, and it was determined to be positive when the fluorescence intensity increased significantly compared to Valproic acid, and negative when it did not significantly increase.
- the test compound was dissolved in DMSO and used, and added to the cells so that the final DMSO concentration was 1%.
- the fluorescence intensity of the comparative compound 4c increased significantly (Dunnett's test (significance level of less than 5%)) at a concentration of 20 ⁇ M, and was determined to be positive.
- the comparative control compound has phospholipidosis-inducing ability, but the compound (I) of the present invention has no phospholipidosis-inducing ability.
- the AST value of the solvent-administered group was 34 to 40 U / L, whereas the AST value of the compound 46b described in the example was 47 U / L, which was almost unchanged. Increased statistically significantly to 145 U / L.
- the compound (I) of the present invention was significantly less hepatotoxic than the comparative compound.
- mice Female, 7 weeks old, Charles River, Japan. Intravenously, mice were passively sensitized. 24 hours after sensitization, 20 ⁇ L of 0.38% DNFB (SIGMA) dissolved in acetone: olive oil (4: 1) was applied to the mouse pinna to induce inflammation. After induction, the thickness of the auricle was measured over time using a Digimatic Indicator (Mitutoyo) for up to 24 hours. The test compound was dissolved in ethanol, and 20 ⁇ L of 0.5 w / v% was applied to the auricle 1 hour before induction.
- SIGMA DNFB
- olive oil olive oil
- the swelling rate of the auricle was calculated by the following formula.
- the AUC (below the curve when the horizontal axis represents the time after initiation and the vertical axis represents the ear swelling rate) Area,% ⁇ hr) was calculated, and AUC between 0 and 4 hours after induction was regarded as an immediate reaction, and AUC between 5 and 10 hours after was regarded as a delayed reaction.
- Auricular swelling rate (%) (AB) / B ⁇ 100
- B Thickness of the auricle before eviction
- the compounds 46b and 50b described in the Examples suppressed both immediate and late ear pinna swelling (inhibition rates of the immediate reactions of the compounds 46b and 50b: 94.4% and 33. respectively). 4%, inhibition rate of delayed reaction: 93.1% and 50.2%, respectively).
- the test compound is dissolved in ethanol, and 0.5 w / v% is applied to the auricle 20 hours before the induction, or suspended in 0.5% methylcellulose (Wako Pure Chemical Industries). It was orally administered at 30 mg / kg 1 hour ago.
- the compounds 46b and 50b described in the Examples suppressed the swelling of the auricle in both administration routes of oral administration and auricle application (suppression rate after oral administration of the compounds 46b and 50b: 37. 7%, 54.4%, inhibition rate with auricle application: 49.2% and 48.0%, respectively).
- the compound (I) of the present invention showed an excellent allergic dermatitis treatment effect by oral administration or application.
- the compounds 46b and 50b described in the Examples were suspended in 0.5 w / v% methylcellulose (Wako Pure Chemical Industries), and were orally administered once at 3 mg / kg on the day of TNBS administration, and for 4 days from the day after TNBS administration. It was orally administered twice a day at 3 mg / kg. The compound administration on the day of TNBS administration was performed 30 minutes to 1 hour before TNBS administration.
- the gross damage score of the solvent administration group was 6.0 ⁇ 0.9, whereas the gross damage score of the compound 46b described in the example was 3.3 ⁇ 0.7, There was a statistically significant decrease in comparison (Wilcoxon test (significance level less than 5%)).
- the standard of the stool softness score was score 0 for normal stool, score 2 for soft stool, score 4 for diarrhea.
- the onset of colitis was confirmed by the fecal softness score, and then switched from DSS to free drinking water of sterilized ultrapure water.
- the stool softness score was recorded every day for 5 days from the 28th day to the 32nd day after the start of drinking water administration, and the total value of the stool softness score for 5 days was defined as the stool softness score (total).
- test compound is suspended in 0.5 w / v% methylcellulose (Wako Pure Chemical Industries), and is orally administered once at 10 mg / kg on the 27th day after the start of the drinking water administration, and from the 28th day to the 31st day after the start of the drinking water administration. Orally administered twice daily at 10 mg / kg.
- the stool softness score (total) of the solvent administration group was 9.5 ⁇ 0.8
- the stool softness scores (total) of the compounds 46b and 50b described in the examples were 5.7 ⁇ .
- the values were 0.8 and 6.5 ⁇ 0.6, both of which were statistically significantly decreased as compared with the solvent administration group (Wilcoxon test (significance level of less than 1%)).
- the compound (I) of the present invention showed an excellent therapeutic effect on inflammatory bowel disease by oral administration.
- test compound was suspended in 0.5 w / v% methylcellulose (Wako Pure Chemical Industries, Ltd.) and orally administered 30 minutes before administration of the 1 w / v% carrageenan physiological saline suspension.
- Compound 46b described in the Examples was administered at a dose of 100 mg / kg
- Comparative Compound 4 was 100 mg / kg as a comparative control compound
- diclofenac sodium Sigma-Aldrich
- the pain threshold value (mmHg) of compound 46b was significantly increased compared to the pain threshold value (mmHg) of the solvent administration group (Student's t-test (significance level less than 0.1%)). Moreover, the pain threshold value (mmHg) of the compound 46b showed a higher value than the pain threshold value (mmHg) of the comparative compound 4 and diclofenac sodium.
- the compound (I) of the present invention showed an excellent inflammatory pain treatment effect by oral administration compared with the comparative control compound and the comparative control drug.
- the Bennett model is based on the left thigh of Crl: CD (SD) rats (male, 6 weeks old, Charles River, Japan). Four sciatic nerves were prepared by ligating lightly with chromic gut gut (4-0). 14 days after the creation of the Bennett model, the test compound was orally administered, and a planter test was performed 90 minutes after the administration. The planter test was performed by measuring the pain threshold (seconds) of the left footpad (model foot) using a plantar heat stimulator (Plantar test 7370, ugobasil) with the heat stimulus intensity set to 60.
- a plantar heat stimulator Plant test 7370, ugobasil
- test compound was suspended in 0.5 w / v% methylcellulose (Wako Pure Chemical Industries) and orally administered.
- Compound 46b described in the Examples was administered at a dose of 100 mg / kg, and anti-convulsant gabapentin (Toronto Research Chemicals) was administered at a dose of 100 mg / kg as a comparative control drug.
- the Chung model was prepared by completely ligating the L5 and L6 spinal nerves of Crl: CD (SD) rats (male, 6 weeks old, Charles River, Japan) with silk thread (5-0). Seven days after the creation of the Chung model, the test compound was orally administered, and von Frey test was performed 90 minutes after the administration. Further, 15 days after the creation of the Chung model, the test compound was orally administered, and a Planter test was performed 90 minutes after the administration. von Frey test measures the pain threshold (g) of the left footpad (model foot) using a Dynamic Plant Aesthesiometer (37400, Ugobasil) with a maximum pressure of 30.0 g and a time to reach the maximum pressure of 40 seconds. Was done.
- the Planter test was performed by the method described above.
- the test compound was suspended in 0.5 w / v% methylcellulose (Wako Pure Chemical Industries) and orally administered.
- Compound 46b described in the Examples was administered at a dose of 100 mg / kg, and anti-convulsant gabapentin (Toronto Research Chemicals) was administered at a dose of 100 mg / kg as a comparative control drug.
- Fig. 2 shows the results of the plant test of the Bennett model. * And ⁇ marks in the figure indicate statistically significant comparison with the solvent administration group (Student's t test) (**: P ⁇ 0.01; solvent administration group and compound 46b administration) Significant difference between groups, ⁇ : P ⁇ 0.01; significant difference between solvent administration group and gabapentin administration group).
- the pain threshold value (second) of compound 46b was significantly increased compared to the pain threshold value (second) of the solvent administration group (Student t test (significance level of less than 1%)). Moreover, the pain threshold value (second) of the compound 46b showed a higher value than the pain threshold value (second) of gabapentin.
- the pain threshold value of the solvent administration group is 5.8 ⁇ 0.1 g
- the pain threshold value of the compound 46b described in the example is 7.0 ⁇ 0.3 g.
- There was a statistically significant increase compared to the administration group (Student t test (significance level of less than 1%)).
- Fig. 3 shows the results of Plant test of the Chung model. * Mark in the figure indicates statistically significant comparison with the solvent administration group (Student's t test) (**: P ⁇ 0.01; between the solvent administration group and the compound 46b administration group) Significant difference).
- the pain threshold value (second) of compound 46b was significantly increased compared to the pain threshold value (second) of the solvent administration group (Student t test (significance level of less than 1%)). Moreover, the pain threshold value (second) of the compound 46b showed a higher value than the pain threshold value (second) of gabapentin.
- the compound (I) of the present invention showed an excellent therapeutic effect on neuropathic pain by oral administration compared with the comparative control drug.
- novel 2,3-dihydro-1H-inden-2-ylurea derivative and its pharmacologically acceptable salt according to the present invention can be used as a medicament containing them as an active ingredient.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
また、R3bとしては、水素が好ましい。
一般式(IV)に示すカルバマート化合物は、塩基存在下、適当な溶媒中で、一般式(II)に示すアニリン誘導体と一般式(III)に示すクロロギ酸エステルとを反応させることにより合成できる。
一般式(Id)に示すウレア化合物は、塩基存在下、適当な溶媒中で、一般式(IV)に示すカルバマート化合物と一般式(V)に示す2-アミノ-2,3-ジヒドロ-1H-インデン化合物とを反応させることにより合成できる。
一般式(VII)に示すニトロ化合物は、一般式(VI)に示すベンズアルデヒド誘導体に対して、適当な溶媒中で、ニトロ化剤を作用させることにより合成できる。
一般式(VIII)に示すトリフルオロエタノール誘導体は、適当な溶媒中で、必要に応じてフッ化物塩存在下、一般式(VII)に示すベンズアルデヒド誘導体とトリフルオロメチル化剤とを反応させることにより合成できる。
一般式(IX)に示すアニリン誘導体は、適当な溶媒中で、一般式(VIII)に示すニトロ化合物のニトロ基を還元することによって合成できる。還元の方法としては、例えば、接触水素化又は一電子還元が挙げられる。
用いる金属触媒としては、例えば、パラジウム/活性炭、水酸化パラジウム/活性炭又は酸化白金が挙げられるが、パラジウム/活性炭が好ましい。
用いる還元剤としては、例えば、鉄、ニッケル、スズ等の金属単体又は塩化鉄、塩化スズ等の金属塩化物が挙げられるが、鉄が好ましい。
一般式(XIV)に示すヒドロキシシクロアルカン誘導体は、一般式(XII)に示すハロゲン化アリール化合物に対して、適当な溶媒中で、塩基を作用させて得られる中間体に、一般式(XIII)に示すシクロアルカノンを作用させることにより合成できる。
一般式(XV)に示すメチルシクロアルカン誘導体は、一般式(XIV)に示すヒドロキシシクロアルカン誘導体に対して、適当な溶媒中で、ルイス酸存在下でメチル化剤を作用させることにより合成できる。
一般式(XVI)に示すベンズアルデヒド誘導体は、一般式(XV)に示すメチルシクロアルカン誘導体に対して、適当な溶媒中で、ルイス酸存在下でホルミル化剤を作用させることにより合成できる。
1-(5-tert-ブチル-3-(ヒドロキシメチル)-2-メトキシフェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物1)の合成
5-tert-ブチル-2-メトキシ-3-ニトロベンズアルデヒドの合成
5-tert-ブチル-2-ヒドロキシベンズアルデヒド(7.71g、43.3mmol)のアセトニトリル(216mL)溶液を-40℃に冷却し、ニトロニウムテトラフルオロボレート(7.47g、56.2mmol)を加えた。1時間かけて-20℃まで昇温しながら撹拌した。反応液に水を加え、水層から酢酸エチルで抽出した。有機層を飽和食塩水で洗浄した。有機層を無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去した。得られた残渣(8.35g)と、炭酸カリウム(25.9g、187mmol)のDMF(50.0mL)懸濁液に、ヨウ化メチル(8.19mL、131mmol)を加え、室温で15時間撹拌した。反応液に水を加え、ジエチルエーテルで抽出した。有機層を水、ついで飽和食塩水で洗浄した。有機層を無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去することにより得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=100/0~80/20)で精製することにより、表題化合物を7.49g(2工程収率84%)得た。
(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)メタノールの合成
5-tert-ブチル-2-メトキシ-3-ニトロベンズアルデヒド(0.500g、2.10mmol)のメタノール(10.5mL)溶液を0℃に冷却し、水素化ホウ素ナトリウム(0.088g、2.31mmol)を加え、15分撹拌した。反応液に飽和塩化アンモニウム水溶液を加え、室温で10分撹拌した。水層から酢酸エチルで抽出し、有機層を飽和食塩水で洗浄した。有機層を無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去した。得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=10/90~50/50)にて精製することにより、表題化合物を0.486g(収率96%)得た。
(3-アミノ-5-tert-ブチル-2-メトキシフェニル)メタノールの合成
(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)メタノール(0.250g、1.04mmol)の酢酸エチル(10.4mL)溶液に、10%パラジウム/活性炭(0.025g)を加え、水素雰囲気下室温で14時間撹拌した。反応終了後、不溶物をセライト床でろ過し、酢酸エチルで洗浄した。ろ液の溶媒を減圧留去することにより、表題化合物を含む粗生成物を0.219g(定量的)得た。
2,2,2-トリクロロエチル 5-tert-ブチル-3-(ヒドロキシメチル)-2-メトキシフェニルカルバマートの合成
(3-アミノ-5-tert-ブチル-2-メトキシフェニル)メタノール(1.72g、8.23mmol)、N,N-ジイソプロピルエチルアミン(2.15mL、12.3mmol)のTHF(27.4mL)溶液を0℃に冷却し、クロロギ酸2,2,2-トリクロロエチル(1.24mL、9.01mmol)を加え、10分撹拌した。反応液に水を加え、水層から酢酸エチルで抽出し、有機層を飽和食塩水で洗浄した。有機層を無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去した。得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=75/25~50/50)にて精製することにより、表題化合物を2.23g(収率71%)得た。
1-(5-tert-ブチル-3-(ヒドロキシメチル)-2-メトキシフェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物1)の合成
2,2,2-トリクロロエチル 5-tert-ブチル-3-(ヒドロキシメチル)-2-メトキシフェニルカルバマート(1.50g、3.90mmol)、(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(1.28g、4.29mmol)、N,N-ジイソプロピルエチルアミン(2.37mL、13.6mmol)のアセトニトリル(19.5mL)懸濁液を加熱還流した。17時間後放冷し、反応液を減圧濃縮した。得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=50/50~0/100)にて精製することにより、表題化合物を1.09g(収率73%)得た。
1-(5-tert-ブチル-3-(ヒドロキシメチル)-2-メトキシフェニル)-3-((1S,2R)-4-フルオロ-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物3)の合成
1-(5-tert-ブチル-2-メトキシ-3-((S)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物46a)、1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物46b)の合成
1-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロエタノールの合成
5-tert-ブチル-2-メトキシ-3-ニトロベンズアルデヒド(13.5g、57.1mmol)のTHF(57.1mL)溶液を0℃に冷却し、トリメチル(トリフルオロメチル)シラン(10.9mL、74.2mmol)、1.0mol/L テトラn-ブチルアンモニウムフルオリド/THF溶液(5.71mL、5.71mmol)をそれぞれ滴下した。試薬投入後、室温まで昇温させた。3時間撹拌した後、反応液に1mol/L塩酸を加え、室温で2時間撹拌した。水層から酢酸エチルで抽出し、有機層を飽和食塩水で洗浄した。有機層を無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去した。得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=100/0~50/50)にて精製することにより、表題化合物を16.5g(収率94%)得た。
1-(3-アミノ-5-tert-ブチル-2-メトキシフェニル)-2,2,2-トリフルオロエタノールの合成
1-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロエタノール(0.440g、1.43mmol)のエタノール(4.7mL)、水(2.3mL)溶液に、塩化アンモニウム(0.230g、4.30mmol)、鉄粉(0.240g、4.30mmol)を加え、15時間加熱還流した。反応液を室温に戻し、不溶物をセライト床でろ過した。有機溶媒を減圧留去したのち、水層から酢酸エチルで抽出し、有機層を飽和食塩水で洗浄した。有機層を無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去することにより、表題化合物を含む粗生成物を0.397g得た。
2,2,2-トリクロロエチル 5-tert-ブチル-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマートの合成
1-(3-アミノ-5-tert-ブチル-2-メトキシフェニル)-2,2,2-トリフルオロエタノールを含む粗生成物(0.397g)、N,N-ジイソプロピルエチルアミン(0.374mL、2.14mmol)のTHF(4.77mL)溶液を0℃に冷却し、クロロギ酸2,2,2-トリクロロエチル(0.217mL、1.57mmol)を加え、10分撹拌した。反応液に水を加え、水層から酢酸エチルで抽出し、有機層を飽和食塩水で洗浄した。有機層を無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去した。得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=100/0~75/25)にて精製することにより、表題化合物を0.622g(2工程収率96%)得た。
1-(5-tert-ブチル-2-メトキシ-3-((S)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物46a)、1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物46b)の合成
2,2,2-トリクロロエチル 5-tert-ブチル-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマート(0.220g、0.486mmol)、(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.189g、0.632mmol)、N,N-ジイソプロピルエチルアミン(0.423mL、2.43mmol)のアセトニトリル(0.486mL)懸濁液を加熱還流した。14時間後放冷し、反応液を減圧濃縮した。得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=67/33~0/100)にて精製することにより、低極性側の表題化合物46aを0.095g(収率43%)、高極性側の表題化合物46bを0.095g(収率43%)得た。
1-(3-(1-アミノ-2,2,2-トリフルオロエチル)-5-tert-ブチル-2-メトキシフェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物47a、化合物47b)の合成
tert-ブチル 1-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロエチルカルバマートの合成
1-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロエタノール(0.500g、1.62mmol)のアセトニトリル(13mL)溶液に、濃硫酸1.30mL(24.4mmol)を加え、2時間加熱還流した。反応終了後放冷し、反応液を飽和炭酸水素ナトリウム水溶液中に加え、pHを8とした。水層から酢酸エチルで抽出し、有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去した。得られた残渣のTHF(20mL)溶液に、トリエチルアミン(0.32mL、2.31mmol)、ジtert-ブチルジカルボナート(0.510g、2.31mmol)、4-(ジメチルアミノ)ピリジン(0.024g)を加え、室温で4時間撹拌した。反応終了後、メタノールを加え、溶媒を減圧留去した。得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=90/10~0/100)にて精製することにより表題化合物を0.599g(収率97%)得た。
tert-ブチル 1-(5-tert-ブチル-3-(3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレイド)-2-メトキシフェニル)-2,2,2-トリフルオロエチルカルバマートの合成
tert-ブチル 1-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロエチルカルバマート(0.645g、1.58mmol)のメタノール(20mL)溶液に、10%パラジウム/活性炭(0.130g)を加え、室温水素雰囲気下3時間撹拌した。反応終了後、不溶物をセライト床でろ過し、溶媒を減圧留去した。得られた残渣のTHF(7.0mL)溶液に、N,N-ジイソプロピルエチルアミン(0.360mL、2.06mmol)を加え、氷冷下にてクロロギ酸2,2,2-トリクロロエチル(0.235mL、1.74mmol)を加え、室温に戻し30分間撹拌した。反応終了後、メタノールを加え、溶媒を減圧留去し、無色油状物を0.768g得た。この油状物(0.300g)及び(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.220g、0.735mmol)を用い、実施例3〔第4工程〕と同様の反応を行うことにより、表題化合物を0.185g(3工程収率54%)得た。
1-(3-(1-アミノ-2,2,2-トリフルオロエチル)-5-tert-ブチル-2-メトキシフェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物47a、化合物47b)の合成
tert-ブチル 1-(5-tert-ブチル-3-(3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレイド)-2-メトキシフェニル)-2,2,2-トリフルオロエチルカルバマート(0.183g、0.332mmol)を10%塩化水素/メタノール溶液(6.0mL)に溶解させ、室温にて28時間撹拌した。反応終了後、溶媒を減圧留去した。得られた残渣に酢酸エチルと1mol/L水酸化ナトリウム水溶液を加え、pHを10とした。水層から酢酸エチルで抽出し、有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去し、得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=90/10~0/100)にて精製することにより、低極性側の表題化合物47aを0.064g(収率43%)、高極性側の表題化合物47bを0.049g(収率33%)得た。
1-(5-tert-ブチル-2-メトキシ-3-(2,2,2-トリフルオロ-1-(メチルアミノ)エチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物48a、化合物48b)の合成
1-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロエタノンの合成
1-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロエタノール(2.00g、6.51mmol)のジクロロメタン(32.5mL)溶液に、デス-マーチンペルヨージナン(2.90g、6.83mmol)を加え、室温で14時間撹拌した。不溶物をセライト床でろ過し、溶媒を減圧留去した。得られた残渣をカラムクロマトグラフィ(アミンコーティングシリカゲル、ヘキサン/酢酸エチル=75/25~10/90)にて精製することにより、表題化合物を1.81g(収率91%)得た。
1-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロ-N-メチルエタンアミンの合成
1-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロエタノン(0.500g、1.63mmol)、メチルアミン塩酸塩(0.221g、3.28mmol)、トリエチルアミン(0.454mL、3.28mmol)のエタノール(5.0mL)溶液に、チタンテトライソプロポキシド(0.960mL、3.28mmol)を滴下し、室温にて一晩撹拌した。反応液を0℃に冷却し、水素化ホウ素ナトリウム(0.062g、1.63mmol)を加え、室温に戻し撹拌した。反応終了後、水を加え、不溶物をセライト床でろ過し、溶媒を減圧留去した。クロロホルムと飽和炭酸水素ナトリウム水溶液を加え、水層からクロロホルムで抽出した。有機層を飽和食塩水にて洗浄し、無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去することにより得られた残渣をカラムクロマトグラフィ(アミンコーティングシリカゲル、ヘキサン/酢酸エチル=75/25)にて精製することにより、表題化合物を0.413g(収率78%)を得た。
5-tert-ブチル-2-メトキシ-3-(2,2,2-トリフルオロ-1-(メチルアミノ)エチル)アニリンの合成
1-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロ-N-メチルエタンアミン(0.413g、1.29mmol)のメタノール(12.0mL)溶液に10%パラジウム/活性炭(0.041g)を加え、室温水素雰囲気下にて3時間撹拌した。反応終了後、不溶物をセライト床でろ過し、ろ液を減圧溜去した。得られた残渣をカラムクロマトグラフィ(アミンコーティングシリカゲル、ヘキサン/酢酸エチル=90/10~0/100)にて精製することにより、表題化合物を0.215g(収率57%)得た。
2,2,2-トリクロロエチル 1-(5-tert-ブチル-3-(3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレイド)-2-メトキシフェニル)-2,2,2-トリフルオロエチル(メチル)カルバマートの合成
5-tert-ブチル-2-メトキシ-3-(2,2,2-トリフルオロ-1-(メチルアミノ)エチル)アニリン(0.215g、0.741mmol)、N,N-ジイソプロピルエチルアミン(0.350mL、1.95mmol)のTHF(3.5mL)溶液を0℃に冷却し、クロロギ酸2,2,2-トリクロロエチル(0.220mL、1.65mmol)を加え、室温に戻し30分間撹拌した。反応終了後、メタノールを加え、溶媒を減圧留去した。得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=50/50~90/10)にて精製することにより、無色固体を0.312g得た。この無色固体(0.312g)及び(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.190g、0.633mmol)を用い、実施例3〔第4工程〕と同様の反応を行うことにより、表題化合物を0.284g(2工程収率60%)得た。
1-(5-tert-ブチル-2-メトキシ-3-(2,2,2-トリフルオロ-1-(メチルアミノ)エチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物48a、化合物48b)の合成
2,2,2-トリクロロエチル 1-(5-tert-ブチル-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレイド)-2-メトキシフェニル)-2,2,2-トリフルオロエチル(メチル)カルバマート(0.284g、0.443mmol)の酢酸(2.2mL)溶液に、水(0.44mL)と亜鉛(0.087g、1.33mmol)を加え、室温にて一晩撹拌した。反応終了後、不溶物をセライト床でろ過した。ろ液を減圧留去し、得られた残渣に酢酸エチルと1mol/L水酸化ナトリウム水溶液を加え、水層から酢酸エチルで抽出した。有機層を飽和食塩水にて洗浄し、無水硫酸ナトリウムで乾燥、ろ過後、溶媒減圧留去し、得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=90/10~0/100)にて精製して、低極性側の表題化合物48aを0.081g(収率39%)、高極性側の表題化合物48bを0.082g(収率40%)得た。
1-(5-tert-ブチル-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-4-メチル-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物49a、化合物49b)の合成
1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-4-フルオロ-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物50a、化合物50b)の合成
1-(5-tert-ブチル-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-4-クロロ-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物51a、化合物51b)の合成
1-(5-tert-ブチル-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-4-メトキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物52a、化合物52b)の合成
1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-5-フルオロ-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物55a、化合物55b)の合成
1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-1-ヒドロキシ-5-メトキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物57a、化合物57b)の合成
1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-6-フルオロ-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物60a、化合物60b)の合成
1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-1-ヒドロキシ-6-メトキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物62a、化合物62b)の合成
1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-7-フルオロ-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物65a、化合物65b)の合成
1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-1-ヒドロキシ-7-メトキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物67a、化合物67b)の合成
1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-1,7-ジヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物68a、化合物68b)の合成
1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-4,7-ジフルオロ-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物73a、化合物73b)の合成
1-(5-tert-ブチル-2-メトキシ-3-((R)-2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(cis-1-メトキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物79a、化合物79b)の合成
1-(5-ブロモ-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物82a、化合物82b)の合成
5-ブロモ-2-メトキシ-3-ニトロベンズアルデヒドの合成
5-ブロモ-2-メトキシベンズアルデヒド(20.0g、93.0mmol)の硫酸(49.6mL)溶液を-15℃に冷却し、60%硝酸(7.62mL、102mmol)を加え2時間攪拌した。反応液に水を加えて析出した固体を濾取することにより、表題化合物を24.0g(収率99%)得た。
1-(5-ブロモ-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロエタノールの合成
5-ブロモ-2-メトキシ-3-ニトロベンズアルデヒド(12.0g、46.1mmol)を用い、実施例3〔第1工程〕と同様の反応を行うことにより、表題化合物を9.32g(収率61%)得た。
1-(3-アミノ-5-ブロモ-2-メトキシフェニル)-2,2,2-トリフルオロエタノールの合成
1-(5-ブロモ-2-メトキシ-3-ニトロフェニル)-2,2,2-トリフルオロエタノール(9.32g、28.2mmol)を用い、実施例3〔第2工程〕と同様の反応を行うことにより、表題化合物を7.62g(収率90%)得た。
2,2,2-トリクロロエチル 5-ブロモ-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマートの合成
1-(3-アミノ-5-ブロモ-2-メトキシフェニル)-2,2,2-トリフルオロエタノール(1.78g、5.93mmol)を用い、実施例3〔第3工程〕と同様の反応を行うことにより、表題化合物を2.27g(収率80%)得た。
1-(5-ブロモ-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物82a、化合物82b)の合成
2,2,2-トリクロロエチル 5-ブロモ-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマート(1.70g、3.58mmol)及び(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(1.12g、3.75mmol)を用い、実施例3〔第4工程〕と同様の反応を行うことにより、低極性側の表題化合物82aを0.648g(収率38%)、高極性側の表題化合物82bを0.612g(収率36%)得た。
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-モルホリノ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物83a、化合物83b)の合成
1-(3-アミノ-2-メトキシ-5-モルホリノフェニル)-2,2,2-トリフルオロエタノールの合成
1-(3-アミノ-5-ブロモ-2-メトキシフェニル)-2,2,2-トリフルオロエタノール(7.62g、25.4mmol)のDMSO(25.4mL)溶液に、モルホリン(11.1mL、127mmol)、L-プロリン(1.17g、10.1mmol)、炭酸カリウム(14.0g、102mmol)、ヨウ化銅(0.967g、5.08mmol)を加え、110℃で17時間攪拌した。反応液を室温に戻し、飽和塩化アンモニウム水溶液を加えて反応を停止させた後、水層からジエチルエーテルで抽出した。有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去し、得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=60/40~30/70)にて精製することにより、表題化合物を5.32g(収率68%)得た。
2,2,2-トリクロロエチル 2-メトキシ-5-モルホリノ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマートの合成
1-(3-アミノ-2-メトキシ-5-モルホリノフェニル)-2,2,2-トリフルオロエタノール(2.35g、7.67mmol)のTHF(20.4mL)溶液に、クロロギ酸2,2,2-トリクロロエチル(1.14mL、8.28mmol),N,N-ジイソプロピルエチルアミン(4.02mL、23.0mmol)を加え、0℃で15分攪拌した。反応液に水を加えて、水層から酢酸エチルで抽出した。有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去し、得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=80/20~60/40)にて精製することにより、表題化合物を3.45g(収率93%)得た。
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-モルホリノ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物83a、化合物83b)の合成
2,2,2-トリクロロエチル 2-メトキシ-5-モルホリノ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマート(0.090g、0.187mmol)及び(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.062g、0.206mmol)を用い、実施例3〔第4工程〕と同様の反応を行うことにより、低極性側の表題化合物83aを0.032g(収率36%)、高極性側の表題化合物83bを0.024g(収率27%)得た。
1-((1S,2R)-4-フルオロ-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-モルホリノ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物84a、化合物84b)の合成
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-(ピロリジン-1-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物92a、化合物92b)の合成
1-(3-アミノ-2-メトキシ-5-(ピロリジン-1-イル)フェニル)-2,2,2-トリフルオロエタノールの合成
1-(3-アミノ-5-ブロモ-2-メトキシフェニル)-2,2,2-トリフルオロエタノール(0.600g、2.00mmol)、ピロリジン(0.25mL、3.04mmol)を用い、実施例20〔第1工程〕と同様の反応を行うことにより、表題化合物を0.253g(収率44%)得た。
2,2,2-トリクロロエチル 2-メトキシ-5-(ピロリジン-1-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマートの合成
1-(3-アミノ-2-メトキシ-5-(ピロリジン-1-イル)フェニル)-2,2,2-トリフルオロエタノール(0.253g、0.872mmol)を用い、実施例3〔第3工程〕と同様の反応を行うことにより、表題化合物を0.406g(収率99%)得た。
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-(ピロリジン-1-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物92a、化合物92b)の合成
2,2,2-トリクロロエチル 2-メトキシ-5-(ピロリジン-1-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマート(0.233g、0.500mmol)及び(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.165g、0.551mmol)を用い、実施例3〔第4工程〕と同様の反応を行うことにより、低極性側の表題化合物92aを0.058g(収率25%)、高極性側の表題化合物92bを0.068g(収率29%)得た。
1-((1S,2R)-4-フルオロ-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-(ピロリジン-1-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物93a、化合物93b)の合成
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-(ピペリジン-1-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物97a、化合物97b)の合成
1-(3-アミノ-2-メトキシ-5-(ピペリジン-1-イル)フェニル)-2,2,2-トリフルオロエタノールの合成
1-(3-アミノ-5-ブロモ-2-メトキシフェニル)-2,2,2-トリフルオロエタノール(0.300g、1.00mmol)、ピペリジン(0.150mL、1.52mmol)を用い、実施例20〔第1工程〕と同様の反応を行うことにより、表題化合物を0.091g(収率30%)得た。
2,2,2-トリクロロエチル 2-メトキシ-5-(ピペリジン-1-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマートの合成
1-(3-アミノ-2-メトキシ-5-(ピペリジン-1-イル)フェニル)-2,2,2-トリフルオロエタノール(0.080g、0.263mmol)を用い、実施例3〔第3工程〕と同様の反応を行うことにより、表題化合物を0.126g(収率99%)得た。
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-(ピペリジン-1-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物97a、化合物97b)の合成
2,2,2-トリクロロエチル 2-メトキシ-5-(ピペリジン-1-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマート(0.125g、0.261mmol)及び(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.086g、0.287mmol)を用い、実施例3〔第4工程〕と同様の反応を行うことにより、低極性側の表題化合物97aを0.032g(収率26%)、高極性側の表題化合97bを0.034g(収率27%)得た。
1-(5-(アゼパン-1-イル)-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物102a、化合物102b)の合成
1-(3-アミノ-5-(アゼパン-1-イル)-2-メトキシフェニル)-2,2,2-トリフルオロエタノールの合成
1-(3-アミノ-5-ブロモ-2-メトキシフェニル)-2,2,2-トリフルオロエタノール(0.600g、2.00mmol)、ヘキサメチレンイミン(0.298g、3.00mmol)を用い、実施例20〔第1工程〕と同様の反応を行うことにより、表題化合物を0.435g(収率68%)得た。
2,2,2-トリクロロエチル 5-(アゼパン-1-イル)-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマートの合成
1-(3-アミノ-5-(アゼパン-1-イル)-2-メトキシフェニル)-2,2,2-トリフルオロエタノール(0.404g、1.27mmol)を用い、実施例1〔第4工程〕と同様の反応を行うことにより、表題化合物を0.408g(収率65%)得た。
1-(5-(アゼパン-1-イル)-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(化合物102a、化合物102b)の合成
2,2,2-トリクロロエチル 5-(アゼパン-1-イル)-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマート(0.173g、0.350mmol)、(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.115g、0.385mmol)を用い、実施例3〔第4工程〕と同様の反応を行うことにより、低極性側の表題化合物102aを0.045g(収率26%)、高極性側の表題化合物102bを0.050g(収率29%)得た。
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物108a、化合物108b)の合成
4-(4-メトキシフェニル)テトラヒドロ-2H-ピラン-4-オールの合成
4-ブロモアニソール(1.00g、5.35mmol)のTHF(10.0mL)溶液を-78℃に冷却し、2.77mol/L n-ブチルリチウム/n-ヘキサン溶液(2.31mL、6.42mmol)を滴下した。1時間撹拌した後、テトラヒドロ-4H-ピラン-4-オン(0.595mL、6.42mmol)を滴下した。2時間撹拌したのち、反応液に酢酸を加え反応を停止した。室温に戻し、酢酸エチルにて希釈し、有機層を水で洗浄した。有機層を飽和食塩水にて洗浄し、無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去し、得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=20/80~0/100)にて精製することにより、表題化合物を0.680g(収率61%)得た。
4-(4-メトキシフェニル)-4-メチルテトラヒドロ-2H-ピランの合成
4-(4-メトキシフェニル)テトラヒドロ-2H-ピラン-4-オール(0.680g、3.27mmol)のジクロロメタン(16.0mL)溶液を-78℃に冷却し、四塩化チタン(0.720mL、6.53mmol)を滴下した。1時間撹拌した後、1.0mol/L ジメチル亜鉛/n-ヘキサン溶液(13.1mL、13.1mmol)を滴下した。2時間撹拌し、水を加えて反応を停止した。室温に戻し、酢酸エチルと1mol/L塩酸にて希釈し、有機層を水、次いで飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去し、得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=90/10~30/70)にて精製することにより、表題化合物を0.641g(収率95%)得た。
2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)ベンズアルデヒドの合成
4-(4-メトキシフェニル)-4-メチルテトラヒドロ-2H-ピラン(0.518g、2.51mmol)のジクロロメタン(12.0mL)溶液を-15℃に冷却し、四塩化チタン(1.22mL、11.0mmol)を滴下した。20分間撹拌した後、ジクロロメチルメチルエーテル(0.336mL,3.77mmol)を滴下した。1時間撹拌した後、1mol/L塩酸を加え反応を停止した。反応液を酢酸エチルで希釈し、有機層を水、次いで飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去し、表題化合物を含む粗生成物を0.719g得た。
2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)-3-ニトロベンズアルデヒドの合成
2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)ベンズアルデヒドを含む粗生成物(0.719g)の酢酸エチル(10.0mL)溶液を-40℃に冷却し、ニトロニウムテトラフルオロボレート(0.597g、4.49mmol)を加えた。2時間かけて撹拌しながら-10℃まで昇温させた。反応液に水を加え、酢酸エチルで希釈し、有機層を水、飽和炭酸水素ナトリウム水溶液、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥、ろ過後、溶媒を減圧留去し、得られた残渣をカラムクロマトグラフィ(シリカゲル、ヘキサン/酢酸エチル=90/10~30/70)にて精製することにより、表題化合物を0.644g(2工程収率92%)得た。
2,2,2-トリフルオロ-1-(2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)-3-ニトロフェニル)エタノールの合成
2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)-3-ニトロベンズアルデヒド(0.644g、2.30mmol)を用い、実施例3〔第1工程〕と同様の反応を行うことにより、表題化合物を0.697g(収率87%)得た。
1-(3-アミノ-2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)フェニル)-2,2,2-トリフルオロエタノールの合成
2,2,2-トリフルオロ-1-(2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)-3-ニトロフェニル)エタノール(0.697g、1.99mmol)を用い、実施例3〔第2工程〕と同様の反応を行うことにより、表題化合物を含む粗生成物0.698gを得た。
2,2,2-トリクロロエチル 2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマートの合成
1-(3-アミノ-2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)フェニル)-2,2,2-トリフルオロエタノールを含む粗生成物(0.698g)を用い、実施例1〔第4工程〕と同様の反応を行うことにより、表題化合物を0.708g(2工程収率72%)得た。
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-(4-メチルテトラヒドロ-2H-ピラン-4-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物108a、化合物108b)の合成
2,2,2-トリクロロエチル 2-メトキシ-5-(4-メチルテトラヒドロ-1H-ピラン-4-イル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマート(0.150g、0.303mmol)及び(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.118g、0.394mmol)を用い、実施例3〔第4工程〕と同様の反応を行うことにより、低極性側の表題化合物108aを0.059g(収率40%)、高極性側の表題化合物108bを0.066g(収率44%)得た。
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-tert-ペンチル-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物123a、化合物123b)の合成
2,2,2-トリフルオロ-1-(2-メトキシ-3-ニトロ-5-tert-ペンチルフェニル)エタノールの合成
2-メトキシ-3-ニトロ-5-tert-ペンチルベンズアルデヒド(0.351g、1.40mmol)を用い、実施例3〔第1工程〕と同様の反応を行うことにより、表題化合物を0.337g(収率75%)得た。
1-(3-アミノ-2-メトキシ-5-tert-ペンチルフェニル)-2,2,2-トリフルオロエタノールの合成
2,2,2-トリフルオロ-1-(2-メトキシ-3-ニトロ-5-tert-ペンチルフェニル)エタノール(0.334g、1.04mmol)を用い、実施例3〔第2工程〕と同様の反応を行うことにより、表題化合物を含む粗生成物0.303gを得た。
2,2,2-トリクロロエチル 2-メトキシ-5-tert-ペンチル-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマートの合成
1-(3-アミノ-2-メトキシ-5-tert-ペンチルフェニル)-2,2,2-トリフルオロエタノールを含む粗生成物を用い、実施例3〔第3工程〕と同様の反応を行うことにより、表題化合物を0.208g(2工程収率43%)得た。
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-tert-ペンチル-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物123a、化合物123b)の合成
2,2,2-トリクロロエチル 2-メトキシ-5-tert-ペンチル-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマート(0.200g、0.428mmol)及び(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.128g、0.428mmol)を用い、実施例3〔第4工程〕と同様の反応を行うことにより、低極性側の表題化合物123aを0.073g(収率36%)、高極性側の表題化合物123bを0.078g(収率39%)得た。
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-(1-メチルシクロブチル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物135a、化合物135b)の合成
1-(4-メトキシフェニル)シクロブタノールの合成
4-ブロモアニソール(6.67g、35.7mmol)、シクロブタノン(3.00g、42.8mmol)を用い、実施例26〔第1工程〕と同様の反応を行うことにより、表題化合物を6.06g(収率95%)得た。
1-メトキシ-4-(1-メチルシクロブチル)ベンゼンの合成
1-(4-メトキシフェニル)シクロブタノール(3.00g、16.8mmol)を用い、実施例26〔第2工程〕と同様の反応を行うことにより、表題化合物を2.52g(収率85%)得た。
2-メトキシ-5-(1-メチルシクロブチル)ベンズアルデヒドの合成
1-メトキシ-4-(1-メチルシクロブチル)ベンゼン(1.20g、6.81mmol)を用い、実施例26〔第3工程〕と同様の反応を行うことにより、表題化合物を1.39g(収率99%)得た。
2-メトキシ-5-(1-メチルシクロブチル)-3-ニトロベンズアルデヒドの合成
2-メトキシ-5-(1-メチルシクロブチル)ベンズアルデヒド(1.39g、6.80mmol)を用い、実施例26〔第4工程〕と同様の反応を行うことにより、表題化合物を1.07g(収率63%)得た。
2,2,2-トリフルオロ-1-(2-メトキシ-5-(1-メチルシクロブチル)-3-ニトロフェニル)エタノールの合成
2-メトキシ-5-(1-メチルシクロブチル)-3-ニトロベンズアルデヒド(1.06g、4.25mmol)を用い、実施例3〔第1工程〕と同様の反応を行うことにより、表題化合物を1.17g(収率86%)得た。
1-(3-アミノ-2-メトキシ-5-(1-メチルシクロブチル)フェニル)-2,2,2-トリフルオロエタノールの合成
2,2,2-トリフルオロ-1-(2-メトキシ-5-(1-メチルシクロブチル)-3-ニトロフェニル)エタノール(1.17g、3.66mmol)を用い、実施例3〔第2工程〕と同様の反応を行うことにより、表題化合物を0.955g(収率90%)得た。
2,2,2-トリクロロエチル 2-メトキシ-5-(1-メチルシクロブチル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマートの合成
1-(3-アミノ-2-メトキシ-5-(1-メチルシクロブチル)フェニル)-2,2,2-トリフルオロエタノール(0.950g、3.28mmol)を用い、実施例3〔第3工程〕と同様の反応を行うことにより、表題化合物を1.268g(収率83%)得た。
1-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)-3-(2-メトキシ-5-(1-メチルシクロブチル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)ウレア(化合物135a、化合物135b)の合成
2,2,2-トリクロロエチル 2-メトキシ-5-(1-メチルシクロブチル)-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニルカルバマート(0.270g、0.581mmol)及び(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.183g、0.611mmol)を用い、実施例3〔第4工程〕と同様の反応を行うことにより、低極性側の表題化合物135aを0.108g(収率40%)、高極性側の表題化合物135bを0.107g(収率40%)得た。
1-(5-tert-ブチル-2-メトキシ-3-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル)-3-(2,3-ジヒドロ-1H-インデン-2-イル)ウレア(比較化合物1)の合成
1H-NMR (400MHz, CDCl3)δ: 7.85 (1H, d, J=2.1 Hz), 7.23-7.15 (5H, m), 6.67 (1H, s), 5.29-5.23 (2H, m), 4.67-4.61 (1H, m), 3.72 (3H, s), 3.32 (2H, dd, J=16.1, 6.9 Hz), 3.26 (1H, d, J=6.3 Hz), 2.83 (2H, td, J=16.1, 4.6 Hz), 1.26 (9H, s).
MS (ESI):437 ([M+H]+).
1-(5-tert-ブチル-3-(ヒドロキシメチル)-2-メトキシフェニル)-3-(2,3-ジヒドロ-1H-インデン-2-イル)ウレア(比較化合物2)の合成
1H-NMR (400MHz, CDCl3)δ: 7.84-6.90 (7H, m), 5.34 (1H, d, J = 6.8 Hz), 4.65-4.64 (3H, m), 3.72 (3H, s), 3.35-3.29 (2H, m), 2.87-2.82 (2H, m), 2.09 (1H, brs), 1.26 (9H, s).
MS (ESI):369 ([M+H]+).
1-(5-tert-ブチル-3-(2-シアノプロパン-2-イル)-2-メトキシフェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(比較化合物3)の合成
5-tert-ブチル-1-(クロロメチル)-2-メトキシ-3-ニトロベンゼンの合成
(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)メタノール(4.59g、19.2mmol)のクロロホルム(20mL)溶液に、塩化チオニル(2.80mL、38.4mmol)を加え、還流下で一晩攪拌した。混合液を室温に冷却後、減圧留去し、残渣に水を加えた。酢酸エチルで抽出した後、無水硫酸ナトリウムで乾燥し、減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル/n-ヘキサン=0/100~30/70)にて精製することにより、表題化合物を1.95g(収率39%)得た。
2-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)アセトニトリルの合成
5-tert-ブチル-1-(クロロメチル)-2-メトキシ-3-ニトロベンゼン(1.93g、7.49mmol)のジオキサン(5.0mL)、エタノール(5.0mL)、水(2.5mL)混合溶液に、シアン化カリウム(0.980g、15.0mmol)を加え、還流下で2時間攪拌した。混合液を室温に冷却後、減圧留去し、残渣に水を加えた。酢酸エチルで抽出した後、無水硫酸ナトリウムで乾燥し、減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル/n-ヘキサン=0/100~30/70)にて精製することにより、表題化合物を1.84g(収率99%)得た。
2-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2-メチルプロパンニトリルの合成
水素化ナトリウム(60%)(0.097g、2.42mmol)のTHF(3.2mL)懸濁液に、2-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)アセトニトリル(0.200g、0.806mmol)を加え、室温で20分攪拌した。この混合液にヨウ化メチル(0.121mL、1.93mmol)を加え、室温で一晩攪拌した。反応混合液に水を加え、酢酸エチルで抽出した。抽出液は無水硫酸ナトリウムで乾燥後、減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル/n-ヘキサン=0/100~30/70)にて精製することにより、表題化合物を0.088g(収率39%)得た。
2-(3-アミノ-5-tert-ブチル-2-メトキシフェニル)-2-メチルプロパンニトリルの合成
2-(5-tert-ブチル-2-メトキシ-3-ニトロフェニル)-2-メチルプロパンニトリル(0.086g、0.311mmol)のエタノール(3.1mL)溶液に、鉄(0.087g、1.56mmol)、塩化アンモニウム(0.083g、1.56mmol)、水(1.6mL)を加え、還流下で3時間攪拌した。反応混合液を濾過し、エタノールで洗浄した。得られた濾液を減圧留去し、残渣をジクロロメタンに溶かした。この溶液を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥させた。溶媒を減圧留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル/n-ヘキサン=0/100~30/70)にて精製することにより、表題化合物を0.051g(収率67%)得た。
2,2,2-トリクロロエチル 5-tert-ブチル-3-(2-シアノプロパン-2-イル)-2-メトキシフェニルカルバマートの合成
2-(3-アミノ-5-tert-ブチル-2-メトキシフェニル)-2-メチルプロパンニトリル(0.050g、0.202mmol)のTHF(0.6mL)溶液に、クロロギ酸2,2,2-トリクロロエチル(0.052g、0.245mmol)、N,N-ジイソプロピルエチルアミン(0.053mL、0.304mmol)を加え、室温で2時間攪拌した。反応混合液を減圧留去し、得られた残査をシリカゲルカラムクロマトグラフィー(酢酸エチル/n-ヘキサン=0/100~30/70)にて精製して表題化合物を0.086g(定量的)得た。
1-(5-tert-ブチル-3-(2-シアノプロパン-2-イル)-2-メトキシフェニル)-3-((1S,2R)-1-ヒドロキシ-2,3-ジヒドロ-1H-インデン-2-イル)ウレア(比較化合物3)の合成
2,2,2-トリクロロエチル 5-tert-ブチル-3-(2-シアノプロパン-2-イル)-2-メトキシフェニルカルバマート(0.086g、0.203mmol)と(1S,2R)-2-アミノ-2,3-ジヒドロ-1H-インデン-1-オール・L-酒石酸塩(0.067g、0.223mmol)のアセトニトリル(0.8mL)溶液にN,N-ジイソプロピルエチルアミン(0.058mL、0.333mmol)を加え、110℃で一晩攪拌した。反応混合液を減圧留去し、得られた残査をシリカゲルカラムクロマトグラフィー(酢酸エチル/n-ヘキサン=10/90~60/40)にて精製して表題化合物を0.044g(収率51%)得た。
1H-NMR (400MHz, CDCl3)δ: 7.64-7.06 (6H, m), 6.40 (1H, s), 5.66 (1H, d, J = 8.0 Hz), 5.11 (1H, dd, J = 5.4, 5.1 Hz), 4.68-4.61 (1H, m), 3.93 (3H, s), 3.32 (1H, dd, J = 15.9, 7.3 Hz), 2.89 (1H, dd, J = 15.9, 6.6 Hz), 2.14 (1H, d, J = 5.1 Hz), 1.74 (3H, s), 1.73 (3H, s), 1.29 (9H, s).
MS (ESI):422 ([M+H]+).
1-(3-tert-ブチル-1-p-トリル-1H-ピラゾール-5-イル)-3-(4-(2-モルホリノエトキシ)ナフタレン-1-イル)ウレア(比較化合物4)及び1-(3-tert-ブチル-1-p-トリル-1H-ピラゾール-5-イル)-3-(4-(2-モルホリノエトキシ)ナフタレン-1-イル)ウレア・塩酸塩(比較化合物4c)の合成
の合成
3-tert-ブチル-1-p-トリル-1H-ピラゾール-5-アミン・塩酸塩の合成
p-トリルヒドラジン・塩酸塩(76.0g、479mmol)、ピバロイルアセトニトリル(85.0g、679mmol)のメタノール(350mL)溶液を加熱還流した。15時間後、室温まで放冷し、メタノールを減圧留去した。得られた残渣にジエチルエーテルを加え、再結晶を行うことにより、表題化合物を108.2g(収率85%)得た。
2,2,2-トリクロロエチル 3-tert-ブチル-1-p-トリル-1H-ピラゾール-5-イルカルバマートの合成
3-tert-ブチル-1-p-トリル-1H-ピラゾール-5-アミン・塩酸塩(75.0g、282mmol)の酢酸エチル(500mL)懸濁液を0℃に冷却し、水酸化ナトリウム(30.0g、750mmol)の水溶液(250mL)を30分かけて滴下した。さらに30分撹拌した後、クロロギ酸2,2,2-トリクロロエチル(55.2mL、401mmol)を30分かけて滴下した。滴下終了後、室温で1.5時間撹拌した後、有機層と分離した。水層から酢酸エチルで抽出し、有機層と合わせて、水、飽和重曹水、水、飽和食塩水の順で有機層を洗浄した。有機層を無水硫酸ナトリウムで乾燥、ろ過し、溶媒を減圧留去した。得られた残渣にn-ヘキサンを加え、析出した沈殿を濾取する事により、表題化合物を97.81g(収率85%)得た。
4-(2-(4-ニトロナフタレン-1-イルオキシ)エチル)モルホリンの合成
4-ニトロナフタレン-1-オール(10.1g、53.4mmol)、4-(2-クロロエチル)モルホリン・塩酸塩(14.0g、75.2mmol)、水酸化ナトリウム(3.11g、77.8mmol)、炭酸カリウム(17.5g、127mmol)の1-メチルピロリジン-2-オン(180mL)懸濁液を100℃で撹拌した。3時間後、反応液を0℃に冷却し、水(200mL)を加えて撹拌した。析出した結晶を濾取する事により、表題化合物を14.31g(収率88%)得た。
1-(3-tert-ブチル-1-p-トリル-1H-ピラゾール-5-イル)-3-(4-(2-モルホリノエトキシ)ナフタレン-1-イル)ウレア(比較化合物4)の合成
4-(2-(4-ニトロナフタレン-1-イルオキシ)エチル)モルホリン(11.18g、36.9mmol)のメタノール(90mL)、THF(30mL)混合溶液に5%パラジウム/活性炭(0.500g)を加え、水素雰囲気下室温で撹拌した。23時間後、不溶物を濾過し、溶媒を減圧留去することにより得られた残渣に、2,2,2-トリクロロエチル 3-tert-ブチル-1-p-トリル-1H-ピラゾール-5-イルカルバマート(16.1g、39.7mmol)、N,N-ジイソプロピルエチルアミン(8.50mL)、DMSO(30mL)を加え、60℃で撹拌した。18時間後、反応液を室温に戻し、飽和食塩水を加えた。水層から酢酸エチルで抽出した後、無水硫酸ナトリウムで乾燥し、減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル/n-ヘキサン=50/50~酢酸エチル/メタノール=90/10)にて精製する事により表題化合物を13.58g(収率69%)得た。
1-(3-tert-ブチル-1-p-トリル-1H-ピラゾール-5-イル)-3-(4-(2-モルホリノエトキシ)ナフタレン-1-イル)ウレア・塩酸塩(比較化合物4c)の合成
1-(3-tert-ブチル-1-p-トリル-1H-ピラゾール-5-イル)-3-(4-(2-モルホリノエトキシ)ナフタレン-1-イル)ウレア(6.38g、12.1mmol)に0.1N塩酸(121mL)、水(150mL)を加えて溶解させた。溶媒を凍結乾燥法で除去することにより、表題化合物6.91g(定量的)得た。
1H-NMR (400MHz, DMSO-d6)δ: 10.95 (1H,s), 8.96 (1H, s), 8.79 (1H, s), 8.30 (1H, d, J=7.6 Hz), 7.99 (1H, d, J=7.6 Hz), 7.68 (1H, d, J=8.3 Hz), 7.61-7.54 (2H, m), 7.46 (2H, d, J=8.4 Hz), 7.35 (2H, d, J=8.4 Hz), 7.01 (1H, d, J=8.3 Hz), 6.35 (1H, s), 4.58-4.55 (2H, m), 4.01-3.98 (2H, m), 3.83-3.77 (2H, m), 3.73-3.71 (2H, m), 3.57-3.54 (2H, m), 3.33-3.28 (2H, m), 2.39 (3H, s), 1.28 (9H, s).
4-(4-(4-フルオロフェニル)-2-(4-(メチルスルフィニル)フェニル)-1H-イミダゾール-5-イル)ピリジン(比較化合物5)
ヒトp38MAPKαを用いて、本発明の化合物(I)のp38MAPK阻害活性を、Current Medicinal Chemistry(2004年、第11号、p.721-730)に記載の方法を一部改変して検討した。
ヒト全血を用いて、LPS刺激によるTNFα産生に対する本発明の化合物(I)の抑制作用を、Journal of Medicinal Chemistry(2003年、第46巻、p.4676-4686)に記載の方法を一部改変して検討した。
マウスにおいて、LPS投与により誘発されるTNFα産生に対する本発明の化合物(I)の作用を、Journal of Immunology(1992年、第148巻、p.1890-1897)に記載の方法を一部改変して検討した。
被験化合物を10%のHP-β-CD(日本食品化工)に溶解して投与液を調製した(経口投与用の投与液として0.08mg/mL)。BALB/c系マウス(雄、7週齢、日本チャールス・リバー)に、化合物を0.8mg/kgの用量で経口投与し、投与後24時間まで頸静脈又は心臓より経時採血した。得られた血液を遠心分離し血漿を採取した。メタノール抽出法により前処理し、化合物濃度をLC/MS/MS(ESIポジティブモード)により分析した。
Human liver microsomes(Xenotech)を0.5mg/mL含むリン酸緩衝液に、被験化合物を2μMの濃度で混合した後、NADPHを加えて37℃にて最大30分間反応させた。アセトニトリルを加えて、反応を終了させた後、10分間4℃で遠心分離し、上清を回収した。上清をメタノール抽出法により前処理し、化合物濃度をLC/MS/MS(ESIポジティブモード)により分析した。得られた化合物濃度から化合物残存率を算出した。化合物残存率の推移から得られた固有クリアランス値(CLint)を表7に示す。なお、比較対照化合物として、比較化合物3及び比較化合物4c(5μM)を用いた。
本発明の化合物(I)によるリン脂質症誘発能の有無を検討した。実施例記載の化合物46bの評価は、Experimental and Toxicologic Pathology(2007年、第58巻、p.375-382)に記載の方法を一部改変して実施した。
FLR=(FLL-FLLB)/(FLH-FLHB)
FLA=(FLR/FLR(Amiodarone hydrochloride))
FLL : リン脂質蛍光強度
FLLB: リン脂質蛍光測定時のブランク値
FLH : 核酸蛍光強度
FLHB: 核酸蛍光測定時のブランク値
本発明の化合物(I)を0.5%のメチルセルロース(和光純薬工業)に懸濁して50mg/mLの投与液を調製した。ICR系マウス(雄、7週齢、日本チャールス・リバー)に化合物を500mg/kgの用量で経口投与し、投与翌日に後大静脈より採血し、得られた血液を遠心分離し血漿を採取した。血漿中の肝障害マーカーであるAST(アスパラギン酸アミノトランスフェラーゼ)値を生化学自動分析装置(日立7070形、日立製作所)により測定した。なお、比較化合物4は0.5%のカルボキシメチルセルロースナトリウム(和光純薬工業)に懸濁して使用した。
マウスアレルギー性皮膚炎モデルの皮膚腫脹反応に対する本発明の化合物(I)の作用を検討した。アレルギー性皮膚炎モデルとして、文献(Inflamm.Res.、1998年、第47巻、p.506-511及びInt.Arch.Allergy.Appl.Immunol.、1990年、第92巻、p.356-360)に記載のI型アレルギー性皮膚炎モデル及びIV型アレルギー性皮膚炎モデルを一部改変して用いた。
BALB/c系マウス(雌、7週齢、日本チャールス・リバー)にマウスIgE抗DNP抗体(0.05mg/body、生化学工業)を静脈内投与し、マウスを受動的に感作した。感作24時間後に、マウスの耳介にアセトン:オリーブ油(4:1)に溶解した0.38%DNFB(SIGMA)20μLを塗布して炎症を惹起した。惹起後、24時間までデジマティックインジケータ(Mitutoyo)を用いて耳介の厚みを経時的に測定した。被験化合物は、エタノールに溶解して、惹起1時間前に0.5w/v%を耳介に20μL塗布した。
耳介腫脹率(%)=(A-B)/B×100
A: 惹起後の耳介の厚み
B: 惹起前の耳介の厚み
BALB/c系マウス(雌、7週齢、日本チャールス・リバー)の背部にアセトン:オリーブ油(4:1)に溶解した0.5%DNFB溶液を25μL塗布した。翌日同様の操作を繰り返してマウスを能動的に感作した。感作4日後に、感作マウスの耳介にアセトン:オリーブ油(4:1)に溶解した0.2%DNFB溶液を20μL塗布し、炎症を惹起した。惹起24時間後、デジマティックインジケータ(Mitutoyo)を用いて耳介の厚みを測定した。被験化合物は、エタノールに溶解して、惹起1時間前に0.5w/v%を耳介に20μL塗布するか、又は、0.5%のメチルセルロース(和光純薬工業)に懸濁して、惹起1時間前に30mg/kgで経口投与した。耳介の腫脹率は、下式により算出した。
耳介腫脹率(%)=(A-B)/B×100
A: 惹起後の耳介の厚み
B: 惹起前の耳介の厚み
この結果から明らかな通り、本発明の化合物(I)は、経口投与又は塗布により、優れたアレルギー性皮膚炎治療効果を示した。
炎症性腸疾患モデルの大腸障害に対する本発明の化合物(I)の作用を検討した。炎症性腸疾患モデルとして、文献(Gastroenterology、1989年、第96巻、p.29-36及びAm.J.Physiol.Gastrointest.Liver Physiol.、2004年、第287巻、p.G115-124)に記載のTNBS誘発大腸炎モデル及びDSS誘発慢性大腸炎モデルを一部改変して用いた。
Slc:Wistar系ラット(雄、12週齢、日本エスエルシー)に、エタノールに溶解したTNBS(和光純薬工業)を、麻酔下で直腸内投与し、TNBS溶液を直腸内に1時間保持することにより大腸炎モデルを作製した。なお、TNBS投与2日前からTNBS投与日までラットは絶食させておいた。TNBS投与日から5日後に大腸を摘出し、大腸傷害の指標として肉眼的ダメージスコア(癒着スコア、下痢スコア及び潰瘍スコアの合計値)を記録した。肉眼的ダメージスコアは、Dubigeonらのスコア(Eur. J.Pharmacol.、2001年、第431巻、p.103-110)及びVenkovaらのスコア(J.Pharmacol.Exp.Ther.、2004年、第308巻、p.206-213)に基づいて算出した。
BALB/cCrSlc系マウス(雌、9週齢、日本エスエルシー)に、滅菌超純水に溶解したDSS(分子量36~50kDa;MP Biomedicals)を飲水投与開始日(これを飲水投与開始後0日目とする)から5日間自由飲水投与した後、滅菌超純水の5日間自由飲水投与に切り換えた。このサイクルを再度繰り返し、さらに7日間DSSを自由飲水投与することにより大腸炎モデルを作製した。大腸炎症状の指標として、便軟度スコアを用いた。便軟度スコアの基準は、正常便の場合:スコア0、軟便の場合:スコア2、下痢の場合:スコア4とした。飲水投与開始後27日目に便軟度スコアにより大腸炎発症を確認後、DSSから滅菌超純水の自由飲水投与に切り換えた。飲水投与開始後28日目から32日目まで便軟度スコアを連日5日間記録し、5日間の便軟度スコアの合計値を、便軟度スコア(トータル)とした。被験化合物は、0.5w/v%メチルセルロース(和光純薬工業)に懸濁して、飲水投与開始後27日目に10mg/kgで1回経口投与し、飲水投与開始後28日目から31日目まで、10mg/kgで1日2回経口投与した。
疼痛モデルの痛覚過敏に対する本発明の化合物(I)の作用を検討した。疼痛モデルとして、文献(Anesth. Analg.、2009年、第108巻、p.1680-1687、Pain、1988年、第33巻、p.87-107及びPain、1992年、第50巻、p.355-363)に記載の炎症性疼痛モデル(カラゲニン足浮腫疼痛モデル)及び神経因性疼痛モデル(Bennettモデル及びChungモデル)を一部改変して用いた。
Crl:CD(SD)系ラット(雄、6週齢、日本チャールス・リバー)の左後肢の足蹠に、1w/v%カラゲニン(逗子化学研究所)生理食塩液懸濁液を0.1mL/body皮下投与することによりカラゲニン足浮腫疼痛モデルを作製した。刺激圧が0mmHgから100mmHgに10秒間で上昇するように設定したAnalgesy Meter(TK-201、ユニコム)を用いて、左後肢の足蹠の疼痛閾値(mmHg)を、1w/v%カラゲニン生理食塩液懸濁液の投与後90分に測定した。被験化合物は、0.5w/v%メチルセルロース(和光純薬工業)に懸濁して、1w/v%カラゲニン生理食塩液懸濁液投与30分前に経口投与した。実施例記載の化合物46bは、100mg/kgの用量で投与し、比較対照化合物として比較化合物4を100mg/kg、比較対照薬として非ステロイド性抗炎症薬であるジクロフェナックナトリウム(Sigma-Aldrich)を3mg/kgの用量で投与した。
Bennettモデルは、Crl:CD(SD)系ラット(雄、6週齢、日本チャールス・リバー)の左大腿部の坐骨神経の4ヶ所をクロミックガットグット(4-0)で軽く結紮することにより作製した。Bennettモデル作製14日後に、被験化合物を経口投与し、その投与後90分にPlantar testを行った。Plantar testは、熱刺激強度を60に設定した足底熱刺激装置(Plantar test 7370、ウゴバジル)を用いて左足蹠(モデル足)の疼痛閾値(秒)を測定することにより行った。被験化合物は、0.5w/v%メチルセルロース(和光純薬工業)に懸濁して、経口投与した。実施例記載の化合物46bは、100mg/kgの用量で投与し、比較対照薬として抗痙攣薬のガバペンチン(Toronto Research Chemicals)を100mg/kgの用量で投与した。
Claims (8)
- 一般式(Ia)で示される、2,3-ジヒドロ-1H-インデン-2-イルウレア誘導体又はその薬理学的に許容される塩。
- R3bは、水素であり、
R3a及びR4aは、R6O-であり、
R4bは、炭素数3~6のアルキル、炭素数3~8のシクロアルキル(1~3個のそれぞれ独立したR6で置換されていてもよく、環を構成する1~3個のメチレンは、それぞれ独立して、-O-、-S-、-C(O)-又は-N(R6)-に置き換わっていてもよく、ベンゼン環と直接結合した炭素原子は、窒素原子に置き換わっていてもよい)又はハロゲンであり、
R5は、それぞれ独立して、R6O-又はハロゲンである、
請求項1記載の2,3-ジヒドロ-1H-インデン-2-イルウレア誘導体又はその薬理学的に許容される塩。 - R3aは、ヒドロキシであり、
R4aは、メトキシ又はエトキシであり、
R4bは、2-プロピル、2-ブチル、2-メチル-2-プロピル、2-メチル-2-ブチル、ピロリジニル、ピペリジニル、アゼパニル、モルホリニル又はブロモであり、
R5は、ヒドロキシ、メトキシ、エトキシ、フルオロ、クロロ又はブロモであり、
Xは、ヒドロキシ、アミノ、メチルアミノ又はジメチルアミノである、
請求項1又は2記載の2,3-ジヒドロ-1H-インデン-2-イルウレア誘導体又はその薬理学的に許容される塩。 - R4aは、メトキシであり、
R4bは、2-メチル-2-プロピルであり、
Xは、ヒドロキシである、
請求項1~3のいずれか一項記載の2,3-ジヒドロ-1H-インデン-2-イルウレア誘導体又はその薬理学的に許容される塩。 - 請求項1~4のいずれか一項記載の2,3-ジヒドロ-1H-インデン-2-イルウレア誘導体又はその薬理学的に許容される塩を有効成分として含有する、医薬。
- 請求項1~4のいずれか一項記載の2,3-ジヒドロ-1H-インデン-2-イルウレア誘導体又はその薬理学的に許容される塩を有効成分として含有する、アレルギー性皮膚炎の治療剤又は予防剤。
- 請求項1~4のいずれか一項記載の2,3-ジヒドロ-1H-インデン-2-イルウレア誘導体又はその薬理学的に許容される塩を有効成分として含有する、炎症性腸疾患の治療剤又は予防剤。
- 請求項1~4のいずれか一項記載の2,3-ジヒドロ-1H-インデン-2-イルウレア誘導体又はその薬理学的に許容される塩を有効成分として含有する、疼痛の治療剤又は予防剤。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10820624.4A EP2484661B1 (en) | 2009-09-30 | 2010-09-30 | 2,3-dihydro-1h-indene-2-ylurea derivative and pharmaceutical application of same |
CA2774040A CA2774040C (en) | 2009-09-30 | 2010-09-30 | 2, 3-dihydro-1h-inden-2-yl urea derivatives and medical uses thereof |
ES10820624.4T ES2634470T3 (es) | 2009-09-30 | 2010-09-30 | Derivado de 2,3-dihidro-1H-inden-2-ilurea y aplicación farmacéutica del mismo |
JP2010540741A JP5573677B2 (ja) | 2009-09-30 | 2010-09-30 | 2,3−ジヒドロ−1h−インデン−2−イルウレア誘導体及びその医薬用途 |
AU2010301449A AU2010301449B2 (en) | 2009-09-30 | 2010-09-30 | 2,3-dihydro-1H-indene-2-ylurea derivative and pharmaceutical application of same |
KR1020127008178A KR101413533B1 (ko) | 2009-09-30 | 2010-09-30 | 2,3-디히드로-1h-인덴-2-일우레아 유도체 및 그 의약 용도 |
US13/497,819 US8653304B2 (en) | 2009-09-30 | 2010-09-30 | 2,3-dihydro-1H-indene-2-yl urea derivative and pharmaceutical application of same |
DK10820624.4T DK2484661T3 (en) | 2009-09-30 | 2010-09-30 | 2,3-DIHYDRO-1H-INDEN-2-YL URINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME |
PL10820624T PL2484661T3 (pl) | 2009-09-30 | 2010-09-30 | Pochodna 2,3-dihydro-1h-inden-2-ylomocznika i jej zastosowanie farmaceutyczne |
CN201080043700.9A CN102574781B (zh) | 2009-09-30 | 2010-09-30 | 2,3-二氢-1h-茚-2-基脲衍生物及其药物用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009227411 | 2009-09-30 | ||
JP2009-227411 | 2009-09-30 | ||
JP2010083722 | 2010-03-31 | ||
JP2010-083722 | 2010-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011040509A1 true WO2011040509A1 (ja) | 2011-04-07 |
Family
ID=43826321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/067047 WO2011040509A1 (ja) | 2009-09-30 | 2010-09-30 | 2,3-ジヒドロ-1h-インデン-2-イルウレア誘導体及びその医薬用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8653304B2 (ja) |
EP (1) | EP2484661B1 (ja) |
JP (1) | JP5573677B2 (ja) |
KR (1) | KR101413533B1 (ja) |
CN (1) | CN102574781B (ja) |
AU (1) | AU2010301449B2 (ja) |
CA (1) | CA2774040C (ja) |
DK (1) | DK2484661T3 (ja) |
ES (1) | ES2634470T3 (ja) |
HU (1) | HUE032947T2 (ja) |
PL (1) | PL2484661T3 (ja) |
PT (1) | PT2484661T (ja) |
WO (1) | WO2011040509A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017038870A1 (ja) * | 2015-08-31 | 2017-03-09 | 東レ株式会社 | 尿素誘導体及びその用途 |
WO2017108737A1 (en) | 2015-12-23 | 2017-06-29 | Chiesi Farmaceutici S.P.A. | 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors |
US10280145B2 (en) | 2015-08-31 | 2019-05-07 | Toray Industries, Inc. | Urea derivative and use therefor |
US10519106B2 (en) | 2015-08-31 | 2019-12-31 | Toray Industries, Inc. | Urea derivative and use therefor |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03261755A (ja) | 1989-05-25 | 1991-11-21 | Takeda Chem Ind Ltd | ベンゾシクロアルカン誘導体,その製造法及び剤 |
WO1993014081A1 (en) | 1992-01-13 | 1993-07-22 | Smithkline Beecham Corporation | Imidazole derivatives and their use as cytokine inhibitors |
WO1999000357A1 (en) | 1997-06-27 | 1999-01-07 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
WO2000043384A1 (en) | 1999-01-19 | 2000-07-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
JP2001526276A (ja) | 1997-12-22 | 2001-12-18 | バイエル コーポレイション | 対称および非対称ジフェニル尿素を用いるp38キナーゼの阻害 |
JP2002517486A (ja) | 1998-06-12 | 2002-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | p38のインヒビター |
WO2002083642A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
JP2003512378A (ja) | 1999-10-21 | 2003-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | p38プロテインキナーゼのインヒビターとしてのヘテロアルキルアミノ置換二環式窒素複素環 |
WO2004082687A1 (en) | 2003-03-18 | 2004-09-30 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as factor xa inhibitors |
JP2005500400A (ja) * | 2001-08-28 | 2005-01-06 | レオ・ファーマ・アクティーゼルスカブ | 新規アミノベンゾフェノン |
JP2005508357A (ja) | 2001-10-17 | 2005-03-31 | グラクソ グループ リミテッド | オキサジアゾリル−ビフェニルカルボキシアミドおよびp38キナーゼ阻害剤としてのその使用 |
JP2006528986A (ja) | 2003-05-20 | 2006-12-28 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
JP2007145819A (ja) | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
WO2007073503A2 (en) | 2005-12-21 | 2007-06-28 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
WO2007103468A2 (en) | 2006-03-07 | 2007-09-13 | Vertex Pharmaceuticals Incorporated | Use of vx-702 for treating rheumatoid arthritis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU632809B2 (en) * | 1989-05-25 | 1993-01-14 | Takeda Chemical Industries Ltd. | Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof |
-
2010
- 2010-09-30 PL PL10820624T patent/PL2484661T3/pl unknown
- 2010-09-30 ES ES10820624.4T patent/ES2634470T3/es active Active
- 2010-09-30 PT PT108206244T patent/PT2484661T/pt unknown
- 2010-09-30 CA CA2774040A patent/CA2774040C/en not_active Expired - Fee Related
- 2010-09-30 EP EP10820624.4A patent/EP2484661B1/en not_active Not-in-force
- 2010-09-30 CN CN201080043700.9A patent/CN102574781B/zh not_active Expired - Fee Related
- 2010-09-30 JP JP2010540741A patent/JP5573677B2/ja not_active Expired - Fee Related
- 2010-09-30 HU HUE10820624A patent/HUE032947T2/en unknown
- 2010-09-30 DK DK10820624.4T patent/DK2484661T3/en active
- 2010-09-30 US US13/497,819 patent/US8653304B2/en not_active Expired - Fee Related
- 2010-09-30 WO PCT/JP2010/067047 patent/WO2011040509A1/ja active Application Filing
- 2010-09-30 AU AU2010301449A patent/AU2010301449B2/en not_active Ceased
- 2010-09-30 KR KR1020127008178A patent/KR101413533B1/ko not_active IP Right Cessation
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03261755A (ja) | 1989-05-25 | 1991-11-21 | Takeda Chem Ind Ltd | ベンゾシクロアルカン誘導体,その製造法及び剤 |
WO1993014081A1 (en) | 1992-01-13 | 1993-07-22 | Smithkline Beecham Corporation | Imidazole derivatives and their use as cytokine inhibitors |
WO1999000357A1 (en) | 1997-06-27 | 1999-01-07 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
JP2001526276A (ja) | 1997-12-22 | 2001-12-18 | バイエル コーポレイション | 対称および非対称ジフェニル尿素を用いるp38キナーゼの阻害 |
JP2002517486A (ja) | 1998-06-12 | 2002-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | p38のインヒビター |
WO2000043384A1 (en) | 1999-01-19 | 2000-07-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
JP2003512378A (ja) | 1999-10-21 | 2003-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | p38プロテインキナーゼのインヒビターとしてのヘテロアルキルアミノ置換二環式窒素複素環 |
WO2002083642A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
JP2005500400A (ja) * | 2001-08-28 | 2005-01-06 | レオ・ファーマ・アクティーゼルスカブ | 新規アミノベンゾフェノン |
JP2005508357A (ja) | 2001-10-17 | 2005-03-31 | グラクソ グループ リミテッド | オキサジアゾリル−ビフェニルカルボキシアミドおよびp38キナーゼ阻害剤としてのその使用 |
WO2004082687A1 (en) | 2003-03-18 | 2004-09-30 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as factor xa inhibitors |
JP2006528986A (ja) | 2003-05-20 | 2006-12-28 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
JP2007145819A (ja) | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
WO2007073503A2 (en) | 2005-12-21 | 2007-06-28 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
WO2007103468A2 (en) | 2006-03-07 | 2007-09-13 | Vertex Pharmaceuticals Incorporated | Use of vx-702 for treating rheumatoid arthritis |
Non-Patent Citations (23)
Title |
---|
AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 287, 2004, pages 15 - 124 |
ANESTH. ANALG., vol. 108, 2009, pages 1680 - 1687 |
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 16, no. 15, 2008, pages 7193 - 7205 |
CELL BIOLOGY AND TOXICOLOGY, vol. 19, 2003, pages 161 - 176 |
CURRENT MEDICINAL CHEMISTRY, 2004, pages 721 - 730 |
DINARELLO ET AL., REV. INFECT. DISEASE, vol. 6, 1984, pages 51 - 95 |
DUBIGEON ET AL., EUR. J PHARMACOL., vol. 431, 2001, pages 103 - 110 |
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, vol. 58, 2007, pages 375 - 382 |
GASTROENTEROLOGY, vol. 37, 2002, pages 409 - 417 |
GASTROENTEROLOGY, vol. 96, 1989, pages 29 - 36 |
INFLAMM. RES., vol. 47, 1998, pages 506 - 511 |
INT. ARCH. ALLERGY. APPL. IMMUNOL., vol. 92, 1990, pages 356 - 360 |
JOURNAL OF IMMUNOLOGY, vol. 148, 1992, pages 1890 - 1897 |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, 2003, pages 4676 - 4686 |
KOJ, BIOCHIM. BIOPHYS. ACTA, vol. 1317, 1996, pages 84 - 94 |
PAIN, vol. 33, 1988, pages 87 - 107 |
PAIN, vol. 50, 1992, pages 355 - 363 |
See also references of EP2484661A4 |
SYNTHESIS, vol. 7, 1998, pages 1029 - 1032 |
TETRAHEDRON LETTERS, vol. 34, no. 52, 1993, pages 8399 - 8402 |
TETRAHEDRON: ASYMMETRY, vol. 6, no. 7, 1995, pages 1535 - 1538 |
VENKOVA ET AL., J PHARMACOL. EXP. THER., vol. 308, 2004, pages 206 - 213 |
YAKUGAKUZASSHI, vol. 99, no. 11, 1979, pages 1111 - 1115 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017038870A1 (ja) * | 2015-08-31 | 2017-03-09 | 東レ株式会社 | 尿素誘導体及びその用途 |
US10280145B2 (en) | 2015-08-31 | 2019-05-07 | Toray Industries, Inc. | Urea derivative and use therefor |
US10519106B2 (en) | 2015-08-31 | 2019-12-31 | Toray Industries, Inc. | Urea derivative and use therefor |
WO2017108737A1 (en) | 2015-12-23 | 2017-06-29 | Chiesi Farmaceutici S.P.A. | 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JPWO2011040509A1 (ja) | 2013-02-28 |
AU2010301449A1 (en) | 2012-03-08 |
CN102574781B (zh) | 2014-02-19 |
EP2484661A1 (en) | 2012-08-08 |
KR20120050504A (ko) | 2012-05-18 |
CN102574781A (zh) | 2012-07-11 |
JP5573677B2 (ja) | 2014-08-20 |
HUE032947T2 (en) | 2017-11-28 |
US8653304B2 (en) | 2014-02-18 |
KR101413533B1 (ko) | 2014-07-01 |
DK2484661T3 (en) | 2017-06-06 |
AU2010301449B2 (en) | 2013-03-14 |
ES2634470T3 (es) | 2017-09-27 |
PT2484661T (pt) | 2017-06-05 |
CA2774040C (en) | 2014-09-09 |
EP2484661A4 (en) | 2013-02-27 |
EP2484661B1 (en) | 2017-04-26 |
PL2484661T3 (pl) | 2017-10-31 |
US20120184735A1 (en) | 2012-07-19 |
CA2774040A1 (en) | 2011-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2599248C2 (ru) | Лизинспецифические ингибиторы деметилазы-1 и их применение | |
RU2602814C2 (ru) | Лизинспецифические ингибиторы деметилазы-1 и их применение | |
CN105481706B (zh) | 一类2‑羟基查尔酮类化合物、其制备方法和用途 | |
KR900001511B1 (ko) | 카테콜 유도체 및 그것을 함유하는 중추신경계 퇴행성질환의 진행방지 및 치료제 | |
WO2005040135A1 (ja) | 抗ストレス薬およびその医薬用途 | |
EP3210969B1 (en) | Kcnq2-5 channel activator | |
JP5573677B2 (ja) | 2,3−ジヒドロ−1h−インデン−2−イルウレア誘導体及びその医薬用途 | |
WO2010010935A1 (ja) | 光学活性なヘテロシクリデン-n-アリールアセトアミド誘導体 | |
CN106554314B (zh) | 苯甲酰胺类衍生物 | |
JP2012211086A (ja) | 関節リウマチの治療剤又は予防剤 | |
JP5330377B2 (ja) | 3,4−ジヒドロキナゾリン誘導体 | |
CN110698411B (zh) | 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途 | |
EP3447045B9 (en) | 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria | |
WO2019088057A1 (ja) | アニリド誘導体及びその医薬用途 | |
CN104744451A (zh) | 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途 | |
TW541295B (en) | A novel substituted alkylteraamine derivative for use as tachykinin antagonist | |
CN109608346B (zh) | 查尔酮双曼尼希碱类化合物、其制备方法和用途 | |
CN109678736B (zh) | 查尔酮曼尼希碱类化合物、其制备方法和用途 | |
WO2019151270A1 (ja) | 環状アミン誘導体及びその医薬用途 | |
CN118290330A (zh) | 一种酰胺衍生物及其在医药上的应用 | |
US20230090255A1 (en) | Magl inhibitor, preparation method therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080043700.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010540741 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10820624 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010301449 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 351/KOLNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2010301449 Country of ref document: AU Date of ref document: 20100930 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2774040 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2010820624 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010820624 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13497819 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20127008178 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |